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Cancer  immune  evasion  is  a major  stumbling  block  in designing  effective  anticancer  therapeutic  strate-
gies.  Although  considerable  progress  has been  made  in  understanding  how  cancers  evade  destructive
immunity,  measures  to counteract  tumor  escape  have  not  kept pace.  There  are  a number  of  factors  that
contribute  to  tumor  persistence  despite  having  a normal  host  immune  system.  Immune  editing  is  one
of  the  key  aspects  why tumors  evade  surveillance  causing  the  tumors  to  lie  dormant  in patients  for
years  through  “equilibrium”  and  “senescence”  before  re-emerging.  In  addition,  tumors  exploit  several
immunological  processes  such  as targeting  the  regulatory  T cell  function  or their secretions,  antigen
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presentation,  modifying  the production  of immune  suppressive  mediators,  tolerance  and  immune  devia-
tion.  Besides  these,  tumor  heterogeneity  and metastasis  also  play a critical  role  in  tumor  growth.  A  number
of  potential  targets  like  promoting  Th1, NK  cell,   T cell  responses,  inhibiting  Treg  functionality,  induc-
tion  of IL-12,  use  of  drugs  including  phytochemicals  have  been  designed  to counter  tumor  progression
with much  success.  Some  natural  agents  and  phytochemicals  merit  further  study.  For example,  use  of
certain  key  polysaccharide  components  from  mushrooms  and  plants  have  shown  to  possess  therapeutic
impact  on  tumor-imposed  genetic  instability,  anti-growth  signaling,  replicative  immortality,  dysregu-
lated metabolism  etc.  In  this  review,  we  will discuss  the  advances  made  toward  understanding  the  basis
of  cancer  immune  evasion  and  summarize  the  efﬁcacy  of  various  therapeutic  measures  and  targets  that
have  been  developed  or are  being  investigated  to enhance  tumor  rejection.
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. Introduction
Cancer remains one of the leading causes of death globally,
ith an estimated 12.7 million cases around the world affecting
oth sexes equally. This number is expected to increase to 21
illion by 2030. The immune system interacts intimately with
umors over the entire process of disease development and pro-
ression to metastasis. This complex cross talk between immunity
nd cancer cells can both inhibit and enhance tumor growth
nd is now classiﬁed as a hallmark of cancer [1]. The balance of
hese actions between and across the hallmarks determines the
ventual outcome, which in the case of clinically overt cancer
esults from evasion of the destructive elements of the immune
esponse by the tumor. Mechanisms resulting in evasion of immune
ttack include the selection of tumor variants resistant to immune
ffectors (sometimes designated “immunoediting”) and progres-
ive formation of an immune suppressive environment within the
umor. Although considerable knowledge has been accumulated
n how tumors avoid immune destruction, discovering effective
ancer therapies still remains a daunting task for the researcher
nd clinician. In this report, we will brieﬂy present an overview of
ow tumors evade immune surveillance by focusing on how the
mmune system reacts to the development of tumors, how certain
ancers evade immunity, and what measures can be taken to erad-
cate cancer. We  will address important aspects of tumor and host
mmune interactions as set out below.
. Tumors and immunity
The involvement of the host immune system in cancer progres-
ion is well established, although greater emphasis has been placed
n tumor eradication by immunity than tumor immune potentiat-
on, which may  be equally important. These interactions between
he immune system and the tumor occur through complex events
hat usually eventually climax either in successful tumor eradica-
ion or immune evasion by the tumor [2].
.1. Relationship between tumor formation and immune
esponses
Tumor development and survival is a chaotically governed pro-
ess involving the interplay between cancer cells, normal stromal
ells and host defense mechanisms. Several other factors such as
ellular changes due to infection or disease-induced stress may
lso contribute to tumor growth or tumor suppression. Generally,
D8+ cytotoxic T cells (CTL) and CD4+ helper T (Th)1 cells curb
ancer development via mechanisms commonly involving their
roduction of interferon (IFN)-  and cytotoxins [3] but other fac-
ors such as chronic inﬂammation may  override these effects to
romote cancer development [4,5]. For example, the risk of overt
epatocellular carcinoma (HCC) appears to be closely linked to the
uration of the Hepatitis B and C viral-induced inﬂammatory stateElsevier  Ltd.  This  is an  open  access  article  under  the CC BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
[6–9]. Compelling evidence has also documented, both in animal
tumor models and in human cancers, that chronic inﬂammation
plays a critical role in the development of colon and pancreatic can-
cers [6]. Therefore, when beneﬁcial acute responses fail to resolve
tumors/cancer, lingering chronic inﬂammation can lead to pro-
motion of tumor cell growth and angiogenesis [6,10]. In addition,
ongoing activity due to autoimmune disease has also been shown
to support development of many cancers including lymphoma
[6,10–12].
2.2. Tumor progression and immunity
Vital fundamental discoveries made over the last few decades
have unequivocally shown that the immune system plays a critical
role in maintaining an equilibrium between immune recognition
and tumor development with a dual capacity to both promote and
suppress tumor growth. These discoveries collectively support the
concept of “immunoediting” and help to explain why tumors can
sometimes lie dormant in patients for years before re-emerging,
and why  tumors grow despite the host having a fully functional
immune system [13]. During cancer immune editing, the immune
system is able to recognize and destroy the most immunologi-
cally vulnerable cancer cells because they present tumor antigens,
resulting in their elimination [14]. Nonetheless, due to genetic
instability, constant tumor cell division can generate with reduced
immunogenicity that can evade immune elimination. This state of
production of new tumor cell variants balanced by the elimina-
tion has been dubbed “equilibrium”, during which the cancer cells
continue to divide, accumulating mutational changes by chance
or in response to immune-induced inﬂammation. Thus, a balance
between immune control and tumor growth is maintained, giving
the appearance of tumor dormancy [15]. However, these processes
eventually enable tumors to impair the capacity of the immune
system to eradicate them by immune suppressive effects or by loss
of target antigen expression. It is at this stage that tumor escape
occurs, resulting in overt clinical cancer. Nonetheless, there may
also be conditions under which tumor cells are truly dormant, for
example by induction of “senescence”. In this case, they would be
likely to remain dormant permanently, as replicative senescence is
generally believed to be irreversible [16].
2.3. Factors that tumors exploit to avoid immune responses
2.3.1. Regulatory cells
Immune suppression in the tumor microenvironment, mediated
by CD4+CD25+ FoxP3+ regulatory T cells (Tregs), or other types of
suppressive cells, seems to be a major mechanism of tumor immune
escape and can be a crucial hurdle for tumor immunotherapy [17].
A number of studies have shown that tumor-derived Tregs have
comparatively higher suppressive activity than naturally occurring
Tregs [18,19]. Tregs are drawn into the tumor microenvironment
via tumor cell-mediated chemokine production [20,21]. Evidence
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lso suggests that transforming growth factor (TGF)-,  produced
y tumor cells among other cells, aids conversion of CD4+ T cells
nto suppressive Tregs in situ [22]. Thus, elimination of Tregs
y anti-CD25 monoclonal antibodies (mAbs) or by other means
ay  promote tumor rejection. Myeloid cells, especially “myeloid-
erived suppressor cells” (MDSCs), modulated dendritic cells (DCs)
nd alternatively-activated M1  and M2 macrophages create an
nﬂammatory microenvironment and can also act as mediators of
umor initiation, angiogenesis, and metastasis [23,24]. Moreover, a
icious cycle may  be instigated in that higher levels of inﬂammatory
ediators confer resistance to apoptosis in MDSCs which would
therwise be subject to downregulation by T cells in complex inter-
ction networks [25]. Thus, CD11b+Gr1+ MDSCs suppress CD8+ T
ell-mediated antitumor immunity [26], one mechanism for which
ay  be TCR -chain downregulation. MDSCs with this phenotype
ccumulate in, for example, melanoma lesions in a manner inti-
ately linked to the inﬂammatory milieu, implying that the tumor
nﬂammatory microenvironment supports MDSC recruitment and
mmunosuppressive activity. Reduction of chronic inﬂammatory
ediators by pharmacological means can reduce the amounts
f MDSC and decrease immunosuppression [27]. CD11b+F4/80+
acrophages having an M2  phenotype produce high levels of
GF-, IL-10, and vascular endothelial growth factor (VEGF) and
romote tumor growth [28–30]. In addition, a number of tumor-
erived factors and gangliosides have been reported to alter DC
henotype. These immature, functionally-impaired DCs have lower
evels of CD80, CD86, CD40, and high indoleamine 2,3-dioxygenase
IDO) expression that also contributes to suppression of T cell
mmunity [31].
.3.2. Defective antigen presentation
It is well established that another fundamental mechanism by
hich tumors evade immune surveillance is by down-modulating
ntigen processing machinery affecting the major histocompat-
bility complex (MHC) I pathway, proteosome subunits latent
embrane protein (LMP)2 and LMP7, transporter associated with
ntigen processing (TAP) protein, and tapasin [32–37]. Thus,
xpression of tumor antigen is downregulated, which can lead to
nhanced tumor incidence and metastasis because cytotoxic T lym-
hocyte (CTL) can no longer recognize target antigens on the tumor
ells [38].
.3.3. Immune suppressive mediators
As alluded to above, tumors can evade immune surveillance
y crippling CTL functionality via production of several immune
uppressive cytokines, either by the cancer cells or by the non-
ancerous cells present in the tumor microenvironment, especially
ncluding immune cells and epithelial cells. TGF- is a chief medi-
tor of this activity [39]. In addition, tumor necrosis factor (TNF)-,
L-1, IL-6, colony stimulating factor (CSF)-1, IL-8, IL-10, and type
 IFNs can also signiﬁcantly contribute to cancer growth [40–44].
n addition to immune suppressive cytokines, other factors such as
EGF produced by tumors, inhibit the differentiation of progenitors
nto DCs [45], thus affecting efﬁcient uptake and antigen presenta-
ion. VEGF and IL-10 and TGF- are also known inhibit maturation
f DCs. DCs retaining the immature phenotype are tolerogenic as
hey do not present antigen in the proper context with appropriate
ostimulation to T cells [46]. Other factors such as tumor gan-
liosides and receptor-binding cancer-associated surface antigen
RCAS1) also contribute to tumor progression [47,48]. Additional
tudies revealed that expression of RCAS1 is associated with apo-
osis of tumor inﬁltrating lymphocytes (TILs) [49,50]. Similarly,
anglioside antigens, on cell surface or shed from cells surface, are
nown to suppress CTL and DC function [51]. Immunosuppress-
ve enzymes such as IDO, arginase, and inhibitor of nuclear factor
appa-B kinase (IKK)2 may  also contribute signiﬁcantly to tumor Biology 35 (2015) S185–S198 S187
progression [52–55] via direct actions on tumor cell proliferation
or through induction of T cell tolerance/suppression [56–58].
2.3.4. Tolerance and immune deviation
Most tumor cells fail to express costimulatory molecules and
can thereby induce anergy or tolerance in T cells by engaging the
T cell receptor in the absence of costimulation [59]. Tumors are
also known to evade immune attack by shifting the balance from
Th1 to Th2 (immune deviation) in a TGF-- and IL-10-dependent
manner [60]. In addition, tumor expression of inhibitory molecules
like programmed cell death (PD)-L1/B7H1 has been shown to cause
deletion or anergy on tumor reactive cells [61,62]. There is also
evidence that down regulation of death receptors prevents death
ligand-mediated killing of tumor cells by both CTLs and natural
killer (NK) cells [63]. Slavin-Chiorini et al. [64] have demonstrated
that CTL studies in conjunction with antibody blocking studies
enhanced antitumor effector activity mainly through CD54. There
are reports to show that p53 tumor suppressive gene is implicated
in the regulation of tumor cell death by CTLs [65]. Thus, factors
promoting tolerance and immune deviation are signiﬁcant contrib-
utors to cancer immune evasion.
2.3.5. Apoptosis
A number of studies have shown that cancer cells delete tumor-
speciﬁc CTLs through apoptosis [66,67]. The different inﬂuences
governing tumor growth and immune evasion strategies are brieﬂy
outlined in Fig. 1.
3. Tumor heterogeneity and immune responses
Cells of the immune system can inhibit tumor growth and pro-
gression through the recognition and rejection of malignant cells
containing initiation mutations. Though tumors originate from a
single transformed cell, due to genetic instability, they commonly
become genetically heterogeneous, exhibiting multiple pheno-
types both in terms of morphology and physiology. They also
display striking heterogeneity in cell surface molecule expression,
proliferative and angiogenic potential [68], which is believed to
stem from morphological and epigenetic plasticity. Thus, the tumor
cells express a wide variety of antigens including some which may
be tumor-speciﬁc or tumor-associated, differentiation antigens,
and lectin-binding sites. These antigens are unevenly distributed
on tumor subpopulations and induce different immune responses
to the same determinant [69]. This tumor antigenic heterogene-
ity has a signiﬁcant effect on genotype, gene expression, cellular
morphology, metabolic activity, motility, and behavior such as pro-
liferation rate, antigen expression, drug response and metabolic
potential [70–74]. Such heterogeneity has important implications
for diagnosis, treatment efﬁcacy, and the identiﬁcation of poten-
tial targets [70,75]. The key aspects of tumor heterogeneity and its
subsequent effects on tumor growth are brieﬂy outlined in Fig. 2.
4. Immune system and cancer metastasis
It is fascinating how cancer cells migrate throughout the body
from their original location to establish themselves at a new loca-
tion [76]. How this exodus of tumor cells occurs is only now
beginning to be understood. In general, cancer cells detach from
the primary tumor and travel through the surrounding tissues and
basement membranes, avoid immune destruction and metasta-
size to distant organs [77,78]. This metastatic process is what is
responsible for most cancer deaths [79–82]. Although there are
several underlying mechanisms of tumor dissemination and colo-
nization [83], the “progression model” which suggests that a series
of mutational events occur either in a subpopulation of primary
S188 D.S. Vinay et al. / Seminars in Cancer Biology 35 (2015) S185–S198
Fig. 1. Tumor growth and immune response. An overview of the different key factors governing tumor formation, progression, and immune evasion. The numbers in
parentheses represent the relevant references in support of the statements made.
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umor or in disseminated cells, resulting in a small fraction of the
ells that acquire full metastatic potential is a well-accepted theory
84]. This view has been corroborated by a number of investiga-
ions [85–88]. Among other factors, once again, it is the TGF-
ecreted by the cancer cells that makes a major contribution to
umor metastasis [89]. In addition, the vasculature also plays an
mportant role in metastatic seeding at different sites. It has been
hown that tumor vasculature hyperstimulated by VEGF often has
educed pericyte coverage and that looser association of such per-
cytes with the endothelium facilitates metastatic dissemination
90]. In addition, hypoxia in and around tumor vessels also con-
ributes to metastatic dissemination of cancer cells in an hypoxia
nducible factor (HIF)-, VEGF-, and inducible nitric oxide synthase
iNOS)-dependent manner [91,92]. Notably, hypoxia promotes the
ormation of pre-metastatic niches through the production of lysyl
xidase [93]. Hypoxia further conditions pre-metastatic niches by events leading to tumor heterogeneity and its consequences for the various aspects
recruiting MDSCs and suppressing NK cell functions [94]. In support
of a role for immunosurveillance in controlling tumor metasta-
sis, a recent study revealed that high expression of Irf7-regulated
genes in primary human breast tumors is associated with pro-
longed bone metastasis-free survival [95]. A brief overview of
the events promoting tumor metastasis and the involvement of
immune responses is provided in Fig. 3.
5. Conventional cancer therapy and the immune system
Although a variety of agents have been screened for their anti-
tumor effects and some have been approved for the treatment
of cancer patients, chemotherapy, radiation therapy, and surgery
remain the mainstays of standard cancer therapeutic strategies.
A downside to these therapies is their ability to cause a transient
immune suppression which in turn increases the risk of infection
D.S. Vinay et al. / Seminars in Cancer
Fig. 3. Immune system and tumor metastasis. Depicted here are the key sequen-
tial events based on the “Progression Model” leading to cancer cells exodus from
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nd is also likely to decrease the immune system’s ability to inhibit
urther development of cancer. For example, standard chemother-
py decreases the host’s native immune competent cells including
 cell populations. However, this transient loss of immune activ-
ty has been shown to return 2–3 weeks after chemotherapy [96].
n addition, patients are at risk for viral, fungal, and parasitic infec-
ions, and when chemotherapy continues long-term, these patients
ay  permanently lose their cell-mediated immune function [97].
evertheless, recent evidence suggests that some chemotherapeu-
ic drugs rely on the induction of anticancer immune responses
or therapeutic activity by inducing a type of tumor cell death
hat is “immunogenic” [98]. The immune-stimulating property of
ome chemotherapeutic drugs, such as anthracyclines and oxalip-
atin, requires preapoptotic translocation of calreticulin (CRT) on
he tumor cell surface, post-apoptotic release of the chromatin-
inding protein high mobility group B1 (HMGB1), and extracellular
elease of ATP. Interestingly, phosphohydrolysis of extracellular
TP by ecto-nucleotidases (i.e. CD39 and CD73) acts as a coun-
erbalancing process to chemotherapy-induced immunogenic cell
eath [99]. Other chemotherapies appear to alter the phenotype of
urviving tumor cells making them better targets for immune cells
100,101]. Radiation therapy has also been shown to impact cell-
ediated immunity. On the one hand, radiotherapy can suppress
ntitumor immunity, presumably due to the high radiosensitivity
f lymphocytes [102]. There are also reports to suggest that high
oses of total lymphocyte irradiation increase T suppressor cell
ctivity and loss of the ability to recognize autoantigens [103].
n the other hand, low doses of radiation result in the gener-
tion of reactive oxygen species (ROS) leading to the activation
f intracellular signaling pathways that induce T cell prolifera-
ion and differentiation [104,105]. Radiation has been shown to
lter the phenotype of cells resulting in increased expression of
eath receptors [106], chemokines [107], adhesion molecules such
s intercellular adhesion molecule (ICAM)-1 and MHC-I [108],
nd costimulatory molecules [109,110] on tumor cells. Moreover,
umor cells surviving radiation have also been shown to be more
ensitive to cytolysis by T cells [108,111]. Radiation has also been
hown to result in the increased expression of proinﬂammatory
ytokines such as TNF- and IL-1 that activate antigen presenting
ells (APCs) [112,113]. Radiotherapy can thus trigger signiﬁcant
ntitumor immune responses, related to the well-known absco-
al effect, that is, the regression of metastases upon irradiation
f the primary tumor, despite the metastasis being outside of the
adiation ﬁeld [114,115]. It is indeed generally accepted that radio-
herapy depends to some degree on the activation of antitumor
mmune responses for its efﬁcacy [116].
Finally, trauma due to surgical resection of tumors has profound
ffects on the immune system because of increased produc-
ion of proinﬂammatory cytokines and other immune modulators
ike IL-6, C-reactive protein (CRP), TNF-, IL-1 etc. [117,118].
lso, decreased delayed-type hypersensitivity (DTH) reactions, Biology 35 (2015) S185–S198 S189
due to surgery, pose a risk for infection [119]. To overcome
surgery-mediated transient immune suppression, the introduction
of laparoscopic methods may  reduce such suppression and thus
decrease tumor growth [120]. Conversely, surgery has also been
shown to induce danger/damage that enhances antitumor efﬁcacy
and reduces metastasis [121]. There is evidence that tumor growth
control can actually potentiate rather than curb metastasis, again
illustrating the general ﬁnding that very similar pathways can have
either inhibitory or facilitatory activity on tumor growth. A case in
point is that chemotherapy, radiotherapy, and biological/targeted
therapies can promote tumor metastasis via the so-called tumor
bed effect [122,123]. Currently, both primary and metastatic can-
cers are treated by similar approaches where radiation is often
the mainstay choice of therapy [124]. Surgery is rarely performed
on metastatic lesions. Thus, these standard anticancer therapies,
although they can be effective alone, will have enhanced therapeu-
tic efﬁcacy when combined with agents that boost the weakened
immune system, if we are able to learn how to avoid potential tumor
growth stimulatory effects.
6. Strategies for cancer immunotherapy
Tumor cells have developed multiple mechanisms for evad-
ing immune surveillance. Current treatments for cancer include
chemotherapy, radiation therapy, immunotherapy, targeted ther-
apy, and surgery which all have limitations and detrimental side
effects [125]. Recent investigations have identiﬁed several classes
of anticancer agents that are targeted, efﬁcient, and have less
adverse side effects. An increasing number of clinical trials are
currently underway to stimulate the immune system to combat
cancer. Important among these include vaccination with peptides
[126], vaccination with DCs [127], vaccination with viral-based vec-
tors [128,129] and immunotherapy with autoreactive effector cells
[130]. Interestingly, there are also studies to show that adminis-
tration of bacteria can increase tumor immunogenicity [131]. For
example, treatment with Clostridium novyi-NT is shown to attract
many inﬂammatory cells such as neutrophils, monocytes, and lym-
phocytes that can kill tumor cells [132]. Especially important will
be the extended use of immunomodulatory antibodies which have
recently yielded such dramatic effects in highly refractory tumors
(see below). Many clinical trials of all these approaches, and espe-
cially combinations thereof, are currently ongoing and hold great
promise.
6.1. Cellular targets
In addition to the obvious targets, the tumor cells themselves,
some of the several regulatory cells including regulatory B cells
or their products implicated in tumor escape are currently being
targeted to promote tumor rejection. For example, IDO is an
immunoregulatory enzyme which suppresses T-cell immunity but
can be targeted in the tumor microenvironment by IDO-reactive
CD8+ T cells. It was shown that IDO-speciﬁc T cells could enhance
tumor immunity by eliminating IDO+ suppressive cells and chang-
ing the regulatory microenvironment [133].
As mentioned above, important among suppressive cells are
Tregs, which are powerful inhibitors of antitumor immunity and
an impediment to successful immunotherapy [22]. In support of
this, inhibition of Tregs by monoclonal antibodies has been shown
to decrease tumor development [134,135]. In addition, other regu-
latory cell populations such as MDSCs which accumulate in spleen,
blood, tumors, and bone marrow of tumor-bearing mice and cancer
patients [136,137] have been considered as important targets for
therapeutic intervention [138]. MDSCs secrete IL-10 and TGF- and
enhance angiogenesis and metastasis by inducing Treg production
S190 D.S. Vinay et al. / Seminars in Cancer Biology 35 (2015) S185–S198
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or  treatment of speciﬁc types of cancers. The numbers in parentheses are the litera
23,139]. Increasing evidence suggests that the M2  macrophages
romote tumor growth and metastasis, and strategies to target
hese cells are also being developed [140]. Type II NK cells are
lso known to contribute to tumor development via their secretion
f characteristic cytokines. About 60% of murine NK cells express
y49 and CD94/NKGA inhibitory receptors, the blockade of which
ugments antitumor activity [3,141,142]. In addition, regulatory
Cs (expressing CD25, PD-1, PD-L1, IL-10, TGF-, kynurenine, IDO,
yclooxygenase (Cox)-2, and arginase (Arg)-1) play a signiﬁcant
ole in tumor development [143] and therapies directed against
hese cells have also been investigated [144].
.2. Molecular targets
In addition to cellular targets, several molecular targets
ncluding cytotoxic T-lymphocyte-associated protein 4 (CTLA)-
 [145], 4-1BB [146], PD1/PD-L1 [147], and activation-inducible
NFR (AITR), T cell immunoglobulin mucin (TIM)-3, Lymphocyte-
ctivation gene (LAG)-3, OX40, CD40, CD39, CD73, A2A [148] and
ancer antigens of different types, such as melanoma-associated
ntigen (MAGE) family members and NY-ESO-1, human telomerase
everse transcriptase (hTERT) and Wilm’s tumor (WT)1 have been
onsidered as important antitumor targets [149]. In melanoma,
AGE, B melanoma antigen (BAGE), and G antigen (GAGE) family
ntigens have been targeted for therapeutic vaccination [150,151].
he L antigen family member (LAGE)-1 gene closely related to NY-
SO-1 may  also be an appropriate target [152]. The preferentially
xpressed antigen in melanoma (PRAME) is also a melanoma-
ssociated antigen recognized by CTL [153]. Human telomerase
ctivity and hTERT expression are detected in a majority (>90%)
f human cancer cells [154]. To increase potential efﬁcacy, hTERT
romoters have been utilized for cancer gene therapy [155,156].
ilms’ tumor gene WT1  is expressed in several different cancers
nd illustrates the general principle that tumor escape from immu-
ity as a result of downregulation of target antigen expression is
nlikely to occur when the gene product has an essential role in
umorigenesis [157]. A number of studies suggest that the WT1
rotein is a promising target for cancer immunotherapy [158,159].
Targeting cell surface molecules other than tumor antigen
argets for antibody-based therapeutic intervention of cancer is
ecoming an important available option for the clinician. Of these,
o far only anti-CTLA-4 (ipilimumab) has been approved for clini-
al use in the USA, Canada, United Kingdom, and European Union
160,161], but PD1 and PD-L1-speciﬁc antibodies will surely be
icensed very soon. Ipilimumab is currently in phase III clinical
rials for the treatment of prostate cancer [162] and for can-
ers of the lung [163] and kidney [164] as well as melanoma.
n one recent trial, administration of the anti-PD-1 antibodyncer. A few of these have entered clinical trials some of which have been approved
ited.
nivolumab showed unprecedented therapeutic objective responses
in 18–28% of patients with advanced non-small-cell lung carci-
noma, melanoma, and renal cell carcinoma [165]. While CTLA-4
and PD-1/PD-L1 blocking Abs have shown efﬁcacy by blocking
inhibitory signals to responding T cells, agonist Ab to OX40 and
4-1BB propel T-cell immunity by sending stimulatory signals. Sev-
eral clinical trials are underway investigating their therapeutic
properties [166]. Targeting Tregs by anti-CD25 antibodies showed
inhibition of neuroblastoma tumors in mice [167]. There are also
data demonstrating that activation of the signal transducer and
activator of transcription (STAT)3 signaling pathway supports
tumor development by inducing accumulations of MDSCs and inhi-
bition of DC differentiation [168]; hence its inactivation leads to
inhibition of cancer development by a DC- and Treg-dependent
mechanism [169].
Targeting immunosuppression by soluble mediators is another
attractive approach for cancer immunotherapy. A plethora of
immunosuppressive factors has been associated with tumorigene-
sis, including TGF-, IDO, arginase, prostaglandin-E2 (PGE2) and
extracellular adenosine. Recent studies have shown that extra-
cellular adenosine, essentially produced by the ecto-nucleotidase
CD73, plays an important role in tumor development and metas-
tasis [170,171,99,172–174]. These ﬁndings are corroborated by
studies using mice deﬁcient in CD73 or the high afﬁnity A2A
adenosine receptor [173–176]. These animals exhibit increased
CTL-mediated antitumor immunity [177]. Inhibition of pH reg-
ulatory molecules and certain heat shock proteins limit cancer
cell-mediated immune suppression. Targeting these molecules
could simultaneously counteract the metastatic potential of cancer
cells and restore antitumor immune surveillance. The above-
mentioned cancer therapeutic targets and their beneﬁcial effects
are brieﬂy outlined in Fig. 4.
6.3. Vaccination therapy (peptide, DNA, and DC)
Several studies demonstrated the efﬁcacy of therapeutic viral
vaccines [178]. Peptide vaccines derived from tumor-associated
antigens (TAA) may  signiﬁcantly contribute to immune enhance-
ment or tumor regression. Many TAAs have been identiﬁed and
molecularly characterized. However, so far only a limited number
of TAA peptides, mostly recognized by CD8+ T cells in melanoma
patients, have been clinically tested. In some clinical trials, partial
or complete tumor regression was observed in 10–30% of patients
[179]. Peptides such as melan-A/MART-127–35 and gp100, which
readily activate speciﬁc T cells in vitro [180] and in vivo [181,182],
show limited immunogenicity when used as vaccines for cancer
patients [183,184]. Alternatively, DNA cancer vaccines may  also
represent an effective approach [185]. Such vaccines, although
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Table  1
Cross-validation of potential targets that may  enhance anticancer immune responses to other cancer hallmarks.
Potential targets
for immune-
modulation
(Promote/enhance)
Th1 responses via
increase number of
NK cells
(Promote/enhance)
 T cell
activities
(Promote/activate)
macrophages
(Inhibit)
Treg lym-
phocytes
(Promote/enhance)
NK cell
activity
(Promote/induce)
IL-12
Other  cancer
hallmarks
Genomic Instability 0 0 0 0 0 0
Sustained
Proliferative
Signaling
0  0 −
[206]
0 0 0
Tumor-Promoting
Inﬂammation
−
[207,208]
−
[209]
+
[210]
+/−
[211–213]
+
[214,215]
+
[216,217]
Evasion of
Anti-growth
Signaling
0 +
[218]
0 +
[219]
+
[220]
0
Resistance to
Apoptosis
0 0 +
[221]
+
[222]
0 −
[223]
Replicative
Immortality
+
[224]
0 0 0 +
[224]
0
Dysregulated
Metabolism
0  0 0 0 0 0
Angiogenesis +
[225–228]
−
[229–232]
+/−
[233]
+
[234]
+
[225]
+
[235]
Tissue Invasion and
Metastasis
+
[236]
+
[237]
−
[238]
+
[239]
+
[240]
+
[241]
Tumor Microenvi- + + +/−
[244
+ + +
T  +/−,  c
h
t
m
i
v
a
n
r
i
s
a
t
p
a
h
I
c
d
n
t
i
N
t
i
r
s
l
p
f
l
s
m
l
t
w
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pronment [242] [243]
he symbols presented above represent as follows: +, complementary; −, contrary;
aving many variants, utilize the same basic principle involving
he isolation of DNA from cancer cells and subsequent transfer,
ost commonly via the intramuscular route, into tumor-bearing
ndividuals. It has been shown that the administration of DNA
accines via the intramuscular route effectively primes both the
daptive as well as innate arms of the immune system [186]. While
aked DNA is quite sturdy and stable at different temperatures, and
etains immune activating abilities, plasmid DNA vaccines are less
mmunogenic [187]. Reﬁnements to the existing DNA vaccination
trategies are showing promising results. Among these, the use of
n electrical pulse, commonly called electropermeabilization, elec-
roporation or electrotransfer [188] is currently used in preclinical
rotocols and has been shown to have strong immune activating
bilities [189]. Recent therapeutic studies involving DNA vaccines
ave shown promise, for example, for the treatment of glioma.
ncorporation of cancer cell DNA into healthy immune competent
ells and subsequent transfer into tumor-bearing mice showed
ecreased tumor burden and increased survival of both sponta-
eous as well as established tumors. Further analysis revealed
hat DNA vaccine-mediated antitumor activity in the above case
nvolved over-production of IFN- and participation of T and
K/lymphokine activated killer (LAK) cells [190,191]. Adoptive
ransfer of peptide-pulsed DC [192] is also an option. In all cases,
t takes a long time to develop such therapies and the newest
esults now being published suggest that peptide vaccinations with
elected multi-peptide vaccines, combined with immunomodu-
atory agents, may  indeed achieve impressive results. Thus, a
hase II multi-center granulocyte macrophage colony stimulating
actor (GM-CSF)-adjuvanted multipeptide vaccine for refractory
ate-stage renal cancer patients has yielded unprecedented 3-year
urvival beneﬁts especially in those patients able to respond to
ore than one peptide, provided they had received a pulse of
ow-dose cyclophosphamide prior to vaccination. It was proposed
hat the cyclophosphamide reduced the Tregs in the patients, for
hich some evidence was presented [193,194]. The United States
DA has approved the use of sipuleucel-T, a cellular product made
f blood APCs cultured with a fusion protein of prostatic acid
hosphatase (PAP) and GM-CSF [195]. Efﬁcacy studies revealed a–246] [247] [248] [249]
ontroversial; 0, no known relationship.
4-month extended median survival in patients with prostate cancer
[196].
6.4. Cross validation
A cross-validation team conducted a peer-reviewed literature
review of the targets and approaches listed in Tables 1 and 2, and
these evidences of cross- hallmark activity are referenced accord-
ingly. This process led to the creation of two unique matrices,
whereby a series of candidate compounds and molecular/cellular
targets were identiﬁed for having immune system evasion mecha-
nistic relevance. The complete mapping of these candidate targets
and actions was screened for known complementary, contrary or
combinations of actions across all cancer hallmarks described in
Hanahan and Weinberg [1]. For example, inhibiting or stimulating
an immune evasion target may  or may  not have been examined
in other hallmark mechanism. Each potential target-hallmark or
approach-hallmark interaction was considered to have either a pro-
or anti-chemotherapeutic effect. There were also mixed indications
or many instances where no known relationship existed. In sum-
mary, the ﬁndings gathered in this effort varied considerably by
each hallmark. These tables provide information that can serve
as a starting point for future basic and translational research on
phytochemical combinations for immune evasion targets and for
chemotherapeutic applications.
6.5. Phytochemicals
Besides these conventional immunotherapeutic approaches,
several phytochemicals have been shown to facilitate tumor
regression. Prominent among these are isothiocyanate, curcumin,
genistein, epigallocatechin gallate, lycopene, resveratrol, and glu-
cosinolates. Some have entered clinical trials and are beginning
to yield encouraging results [197]. There are other natural, plant-
derived or nutrient substances, including ﬂavonoids, omega-3 fatty
acids, zinc, and vitamin C, that are purported to strengthen the
immune system [198–201], yet their roles as nutrients to resolve
inﬂammation or assist in suppressing tumorigenesis are not clear
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Table 2
Cross-validation of phytochemicals that may  enhance anticancer immune responses to other cancer hallmarks.
Approach Ganoderma lucidum
(polysaccharide
fraction)
Trametes versicolor
(protein-bound
polysaccharide-k)
Astragalus membranaceus
(polysaccharide fraction)
Lentinus edodes
(polysaccharide
L-II, lentinan)
Astaxan-thin Polyphenol-
resveratrol analog
HS-1793
Other  cancer hallmarks
Genomic Instability 0 0 0 0 0 0
Sustained Proliferative
Signaling
+
[250]
0 0 +
[251,252]
+
[253–255]
0
Tumor-Promoting
Inﬂammation
+
[256,257]
0 +
[258]
+
[259,260]
+
[261,254]
0
Evasion of Anti-growth
Signaling
+
[262,263]
+
[264]
+
[265]
+
[266]
+
[267]
0
Resistance to Apoptosis +
[268]
0 +
[269]
+
[270]
+
[271]
+
[272]
Replicative
Immortality
+
[273]
0 0 0 0 0
Dysregulated
Metabolism
0  0 0 0 0 0
Angiogenesis +
[274,275]
0 −
[276]
+
[277]
0 +
[278]
Tissue Invasion and
Metastasis
+
[279]
0 +
[280]
+
[281]
+
[282]
+
[283,284]
Tumor + + + + + +
T  +/−,  c
f
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t
t
i
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t
s
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d
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∼Microenvironment [285] [286] [287]
he symbols presented above represent as follows: +, complementary; −, contrary;
rom human studies. Too often, these alternative or complementary
gents are not evaluated with standard sets of clinical outcomes
hat are needed to advance our understanding of how nutri-
ional components and phytochemicals may  enhance tumoricidal
mmunity or inhibit tumor immune evasion mechanisms described
bove. While some dietary supplements have been shown to
nhance the ability of NK cells to identify and destroy dysfunc-
ional cells, such as infected or cancerous cells [202,203], these
tudies have not comprehensively assessed increased T cell pro-
uction of cytokines such as IFN and TNF, or reduced secretion
f immune suppressive factors from tumors. The emerging evi-
ence for dietary supplement doses that far exceed physiological
utrient exposures suggests that some bioactive food components
an even be hazardous [204], and are now largely discouraged
or consumption during cancer treatment [205]. Table 2 summa-
izes potential targets and approaches that may  enhance anticancer
mmune responses.
.6. Adoptive T cell therapy
Autoreactive T cells are potentially tolerant to self-tissues, due to
iverse mechanisms in the periphery [291]. Adoptive T cell therapy
nvolves the isolation and expansion of autologous T cells speciﬁc
or tumor antigen and their subsequent re-infusion into the patient.
umor-reactive T cells such as tumor-inﬁltrating lymphocytes (TIL)
ombined with IL-2 showed potentially interesting results already
n the 1980s, but objective response rate was low in metastatic
elanoma patients [292,293]. In 2002, Rosenberg and colleagues
294,295] introduced a lymphodepletion regimen before admin-
stering adoptive T cell therapy, resulting in elimination of the
mmune-suppressive cells, increase of key cytokines for T cells
uch as IL-7 and IL-15, and creation of a space for T-cell prolifera-
ion. When lymphopenia is induced, remaining peripheral T cells
nitiate homeostatic proliferation to reconstitute the lost T cells,
nd the tolerant autoreactive CD8+ T cells acquire an opportunity
o proliferate and become functional [296,297]. This may be one
echanism by which self-tumor Ag-speciﬁc T cells are increased inancer patients after chemo- or radio-therapy [298,299]. This lym-
hodepletion treatment markedly improved the clinical efﬁcacy
f adoptive cell therapy using TILs, with an objective response in
70% of melanoma patients and complete durable regressions were[288,259] [289] [290]
ontroversial; 0, no known relationship.
found in ∼50% [300]. Rosenberg et al. [301] have demonstrated
objective cancer regression in patients with metstatic melanoma.
Though good clinical outcome has been observed by Rosenberg
et al. [301], generating T cells for adoptive T cell therapy is a
cumbersome process. There have been many efforts to develop a
practical protocol to produce autologous self-tumor Ag-speciﬁc T
cells, but most of them are still complicated and time-consuming
because self-tumor Ag-reactive T cells exist as a minor popula-
tion. Recently, however, an efﬁcient method has been developed
to produce tumor-speciﬁc CD8+ T cells from ∼50 ml of periph-
eral blood mononuclear cells based upon the unique property of
4-1BB (CD137) to be selectively expressed on antigen-engaged T
cells [302]. Clinical trials with various solid tumors are underway
to test the safety and efﬁcacy of the CTLs thus generated. To over-
come major hurdles in the preparation of autologous self-tumor
Ag-speciﬁc T cells, gene-modiﬁed T cells like TCR or chimeric Ag
receptor (CAR)-modiﬁed T cells were developed [303]. Currently,
these gene-modiﬁed T cells are being tested for safety and efﬁ-
cacy in the clinic and clinical results will tell us whether adoptive
T cell therapy could provide a new opportunity for cancer patients
who failed to respond to standard therapies. However, the many
mechanisms of tumor escape discussed above (tumor suppression,
downregulation of target antigens etc.) need to be considered and
counteracted in combination with these modalities.
7. Conclusions
Here we  wish to emphasize that immunotherapeutic
approaches may  advance via the inclusion of holistic or inte-
grative therapy of cancer. Especially, we want to emphasize that
dual approaches which seek to (1) eliminate immune suppressing
factors, and (2) enhance tumor-killing activities will be necessary
to achieve successful cancer therapy. In view of the immune
suppressive factors present in the tumor microenvironment from
the very earliest stages of tumor formation, nontoxic agents
that control or eliminate the immunosuppressive factors can be
used for therapy of cancer or also utilized as cancer control and
chemopreventive agents. A tumor-killing agent requires us to aim
at cross-clonal common targets, which overcome the intra- and
inter-tumoral heterogeneity.
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An in-depth understanding of how tumors evade immune
urveillance will help develop effective therapeutic strategies that
an be used for the beneﬁt of cancer patients.
isclosure
BSK: patents for methods regarding anti-CD137 and adoptive
TL therapeutics. RLW: patent for use of IGFBP-3 as anticancer ther-
py; FDA murine work for Arrium Corporation for Omega 3 fatty
cid anti-adhesion product; Consultant for Ethicon Endosurgery
nd Olympus Corporation regarding surgical staplers and advanced
ndoscopic polypectomy methods. TL: worked with Medtronic in
eveloping a passive immunotherapeutic strategy for treatment
f Alzheimer’s disease. WKD: patent for methods and composi-
ions regarding Th-1 dendritic cells; Consultant of Gerson Lehrman
roup; Medical advisor of Texans for stem cell research.
cknowledgments
This work was supported by grants from the National Cancer
enter, Korea (NCC-1310430-2) and the National Research Foun-
ation (NRF-2005-0093837). W.  Nicol Keith & Alan Bilsland were
upported by the University of Glasgow, Beatson Oncology Centre
und, and Cancer Research UK (http://www.cancerresearchuk.org)
rant C301/A14762.
eferences
[1] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell
2011;144:646–74.
[2] Becker JC, Andersen MH,  Schrama D, Thor Straten P. Immune-suppressive
properties of the tumor microenvironment. Cancer Immunol Immunother
2013;62:1137–48.
[3] Zamarron BF, Chen W.  Dual roles of immune cells and their factors in cancer
development and progression. Int J Biol Sci 2011;7:651–8.
[4] Blackwill F, Mantovani A. Inﬂammation and cancer: back to Virchow? Lancet
2002;357:539–45.
[5] Rakoff-Nahoum S. Why  cancer and inﬂammation. Yale J Biol Med
2007;79:123–30.
[6] Grivennikov SI, Greten FR, Karin M.  Immunity, inﬂammation, and cancer. Cell
2010;140:883–99.
[7] Karin M.  Nuclear factor-kappaB in cancer development and progression.
Nature 2006;441:431–6.
[8] Karin M,  Lawrence T, Nizet V. Innate immunity gone awry: linking microbial
infections to chronic inﬂammation and cancer. Cell 2006;124:823–35.
[9] Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity
promote liver inﬂammation and tumorigenesis by enhancing IL-6 and TNF
expression. Cell 2010;140:197–208.
[10] de Martel C, Franceschi S. Infections and cancer: established associations and
new hypotheses. Crit Rev Oncol Hematol 2009;70:183–94.
[11] Coussens LM,  Werb Z. Inﬂammation and cancer. Nature 2002;420:860–7.
[12] Coussens LM,  Werb Z. Inﬂammatory cells and cancer: think different! J Exp
Med  2001;193:F23–6.
[13] Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting:
from immunosurveillance to tumor escape. Nat Immunol 2002;3:991–8.
[14] Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu
Rev Immunol 2004;22:329–60.
[15] Sawnn JB, Smyth MJ.  Immune surveillance of tumors. J Clin Investig
2007;117:1137–46.
[16] Shay JW,  Roninson IB. Hallmarks of senescence in carcinogenesis and cancer
therapy. Oncogene 2004;23:2919–33.
[17] Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ. Regulatory T cells in
melanoma: the ﬁnal hurdle towards effective immunotherapy? Lancet Oncol
2012;13:e32–42.
[18] Yokokawa J, Cereda V, Remondo C, Gulley JL, Arlen PM, Schlom J, et al.
Enhanced functionality of CD4 + CD25(high)FoxP3+ regulatory T cells in
the  peripheral blood of patients with prostate cancer. Clin Cancer Res
2008;14:1032–40.
[19] Gasparoto TH, de Souza Malaspina TS, Benevides L, de Melo Jr EJ, Costa MR,
Damante JH, et al. Patients with oral squamous cell carcinoma are character-
ized by increased frequency of suppressive regulatory T cells in the blood and
tumor microenvironment. Cancer Immunol Immunother 2010;59:819–28.
[20] Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Speciﬁc recruit-
ment of regulatory T cells in ovarian carcinoma fosters immune privilege and
predicts reduced survival. Nat Med  2004;10:942–9. Biology 35 (2015) S185–S198 S193
[21] Lee I, Wang L, Wells AD, Dorf ME, Ozkaynak E, Hancock WW.  Recruitment of
Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4
chemokine receptor. J Exp Med  2005;201:1037–44.
[22] Zou W.  Regulatory T cells, tumour immunity and immunotherapy. Nat Rev
Immunol 2006;6:295–307.
[23] Murdoch C, Muthana M,  Coffelt SB, Lewis CE. The role of myeloid cells in the
promotion of tumour angiogenesis. Nat Rev Cancer 2008;8:618–31.
[24] Shozaei F, Zhong C, Wu  X, Yu L, Ferrara N. Role of myeloid cells in tumor
angiogenesis and growth. Trends Cell Biol 2008;18:372–8.
[25] Ostrand-Rosenberg S, Sinha P, Chornoguz O, Ecker C. Regulating the sup-
pressors: apoptosis and inﬂammation govern the survival of tumor-induced
myeloid-derived suppressor cells (MDSC). Cancer Immunol Immunother
2012;61:1319–25.
[26] Seung LP, Rowley DA, Dubey P, Schreiber H. Synergy between T-cell immunity
and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad
Sci  USA 1995;92:6254–8.
[27] Umansky V, Sevko A. Overcoming immunosuppression in the melanoma
microenvironment induced by chronic inﬂammation. Cancer Immunol
Immunother 2012;61:275–82.
[28] Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance,
tolerance, and diversity. Curr Opin Immunol 2010;22:231–7.
[29] van Kempen LC, Ruiter DJ, van Muijen GN, Coussens LM.  The tumor microen-
vironment: a critical determinant of neoplastic evolution. Eur J Cell Biol
2003;82:539–48.
[30] Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG,  et al. Macrophage
polarization in tumour progression. Semin Cancer Biol 2008;18:349–55.
[31] Munn DH, Sharma MD,  Lee JR, Jhaver KG, Johnson TS, Keskin DB, et al. Poten-
tial regulatory function of human dendritic cells expressing indoleamine
2,3-dioxygenase. Science 2002;297:1867–70.
[32] Garrido F, Ruiz-Cabello F, Cabrera T, Pérez-Villar JJ, López-Botet M,  Duggan-
Keen M,  et al. Implications for immunosurveillance of altered HLA class I
phenotypes in human tumours. Immunol Today 1997;18:89–95.
[33] Hicklin DJ, Marincola FM,  Ferrone S. HLA class I antigen downregulation in
human cancers: T-cell immunotherapy revives an old story. Mol  Med Today
1999;5:178–86.
[34] Johnsen AK, Templeton DJ, Sy M,  Harding CV. Deﬁciency of transporter for
antigen presentation (TAP) in tumor cells allows evasion of immune surveil-
lance and increases tumorigenesis. J Immunol 1999;163:4224–31.
[35] Restifo NP, Esquivel F, Kawakami Y, Yewdell JW,  Mulé JJ, Rosenberg SA, et al.
Identiﬁcation of human cancers deﬁcient in antigen processing. J Exp Med
1993;177:265–72.
[36] Rotem-Yehudar R, Groettrup M,  Soza A, Kloetzel PM, Ehrlich R. LMP-
associated proteolytic activities and TAP-dependent peptide transport for
class 1 MHC  molecules are suppressed in cell lines transformed by the highly
oncogenic adenovirus 12. J Exp Med  1996;183:499–514.
[37] Seliger B, Maeurer MJ,  Ferrone S. TAP off–tumors on. Immunol Today
1997;18:292–9.
[38] Maeurer MJ,  Gollin SM,  Martin D, Swaney W,  Bryant J, Castelli C, et al. Tumor
escape from immune recognition: lethal recurrent melanoma in a patient
associated with downregulation of the peptide transporter protein TAP-1 and
loss  of expression of the immunodominant MART-1/Melan-A antigen. J Clin
Investig 1996;98:1633–41.
[39] Pasche B. Role of transforming growth factor beta in cancer. J Cell Physiol
2001;186:153–68.
[40] Lind MH,  Rozell B, Wallin RP, van Hogerlinden M,  Ljunggren HG,  Toftgård R,
et  al. Tumor necrosis factor receptor 1-mediated signaling is required for skin
cancer development induced by NF-kappaB inhibition. Proc Natl Acad Sci USA
2004;101:4972–7.
[41] Lin EY, Gouon-Evans V, Nguyen AV, Pollard JW.  The macrophage growth factor
CSF-1 in mammary gland development and tumor progression. J Mammary
Gland Biol Neoplasia 2002;7:147–62.
[42] Klein SC, Jücker M,  Abts H, Tesch H. IL6 and IL6 receptor expression in Burkitt’s
lymphoma and lymphoblastoid cell lines: promotion of IL6 receptor expres-
sion by EBV. Hematol Oncol 1995;13:121–30.
[43] Matsuda M,  Salazar F, Petersson M,  Masucci G, Hansson J, Pisa P, et al. Inter-
leukin 10 pretreatment protects target cells from tumor- and allo-speciﬁc
cytotoxic T cells and downregulates HLA class I expression. J Exp Med
1994;180:2371–6.
[44] Sotomayer EM,  Fu YX, Lopez-Cepero M,  Herbert L, Jimenez JJ, Albarracin C,
et  al. Role of tumor-derived cytokines on the immune system of mice bearing
a  mammary adenocarcinoma. II. Downregulation of macrophage-mediated
cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating
factor. J Immunol 1991;147:2816–23.
[45] Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al.
Production of vascular endothelial growth factor by human tumors inhibits
the functional maturation of dendritic cells. Nat Med  1996;2:1096–103.
[46] Gabrilovic D. Mechanisms and functional signiﬁcance of tumor induced
dendritic-cell defects. Nat Rev Immunol 2004;4:941–52.
[47] McKallip R, Li R, Ladisch S. Tumor gangliosides inhibit the tumor-speciﬁc
immune response. J Immunol 1999;163:3718–26.
[48] Nakashima M,  Sonoda K, Watanabe T. Inhibition of cell growth and induction
of  apoptotic cell death by the human tumor-associated antigen RCAS1. Nat
Med  1999;5:938–42.
[49] Nakabayashi H, Nakashima M,  Hara M,  Toyonaga S, Yamada SM, Park KC, et al.
Clinic-pathological signiﬁcance of RCAS1 expression in gliomas: a potential
mechanism of tumor immune escape. Cancer Lett 2007;246:182–9.
S ancer194 D.S. Vinay et al. / Seminars in C
[50] Sonoda K, Miyamoto S, Nakashima M,  Wake N. The biological role of unique
molecule RCAS1: a bioactive marker that induces connective tissue remodel-
ing and lymphocyte apotosis. Front Biosci 2008;13:1106–16.
[51] Birkle S, Zeng G, Gao L, Yu RK, Aubry J. Role of tumor-associated ganglisodes
in cancer progression. Biochemie 2003;85:455–63.
[52] Muller AJ, Prendergast GC. Marrying immunotherapy with chemotherapy:
why  say IDO? Cancer Res 2005;65:8065–8.
[53] Mills CD, Shearer J, Evans R, Caldwell MD.  Macrophage arginine metabolism
and the inhibition or stimulation of cancer. J Immunol 1992;149:2709–14.
[54] Boutard V, Havouis R, Fouqueray B, Philippe C, Moulinoux JP, Baud L. Trans-
forming growth factor-beta stimulates arginase activity in macrophages.
Implications for the regulation of macrophage cytotoxicity. J Immunol
1995;155:2077–84.
[55] Xia Y, Yeddula N, Leblanc M,  Ke E, Zhang Y, Oldﬁeld E, et al. Reduced cell
proliferation by IKK2 depletion in a mouse lung-cancer model. Nat Cell Biol
2012, http://dx.doi.org/10.1038/ncb2428.
[56] Prenderghast GC. Immune escape as a fundamental trait of cancer: focus on
IDO. Oncogene 2008;27:3889–900.
[57] Munder M.  Arginase: an emerging key player in the mammalian immune
system. Br J Pharmacol 2009;158, 638-351.
[58] Kim HJ, Hawke N, Baldwin AS. NF-B and IKK as therapeutic targets in cancer.
Cell Death Differ 2006;13:738–47.
[59] Staveley-O’Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S,
et al. Induction of antigen-speciﬁc T cell anergy: an early event in the course
of  tumor progression. Proc Natl Acad Sci USA 1998;95:1179–83.
[60] Maeda H, Shiraishi A. TGF-beta contributes to the shift toward Th2-type
responses through direct and IL-10-mediated pathways in tumor-bearing
mice. J Immunol 1996;156:73–8.
[61] Driessens G, Kline J, Gajewski TF. Costimulatory and inhibitory receptors in
anti-tumor immunity. Immunol Rev 2009;229:126–44.
[62] Topalian SL, Drake CG, Pardoll DM.  Targeting PD-1/B7-H1 (PD-L1) pathway
to activate antitumor immunity. Curr Opin Immunol 2012;24:207–12.
[63] French LE, Tschopp J. Defective death receptor signaling as a cause of tumor
immune escape. Semin Cancer Biol 2002;12:51–5.
[64] Slavin-Chiorini DC, Catalfamo M,  Kudo-Saito C, Hodge JW,  Scholm J, Sabze-
vari H. Ampliﬁcation of the lytic potential of effector/memory CD8+ cells by
vector-based enhancement of ICAM-1(CD54) in target cells: implications for
intrtumoral vaccine therapy. Cancer Gene Ther 2004;11:665–80.
[65] Chouaib S, meslin F, Thiery J, Mami-Chouaib F. Tumor resistance to speciﬁc
lysis: a major hurdle for successful immunotherapy of cancer. Clin Immunol
2009;130:34–40.
[66] Bogen B. Peripheral T cell tolerance as a tumor escape mechanism: deletion
of  CD4+ T cells speciﬁc for a monoclonal immunoglobulin idiotype secreted
by a plasmacytoma. Eur J Immunol 1996;26:2671–9.
[67] Lauritzsen GF, Hofgaard PO, Schenck K, Bogen B. Clonal deletion of thymocytes
as  a tumor escape mechanism. Int J Cancer 1998;78:216–22.
[68] Marusky A, Polyak K. Tumor heterogeneity: causes and consequences.
Biochim Biophys Acta 2010;1805:105–17.
[69] Miller FR. Intratumor immunologic heterogeneity. Cancer Metastasis Rev
1982;1:319–34.
[70] Campbell LL, Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal
evolution? Cell Cycle 2007;6:2322–8.
[71] Dick JE. Stem cell concepts renew cancer research. Blood 2008;112:4793–807.
[72] Fiddler IJ, Hart IR. Biological diversity in metastatic neoplasms: origins and
implications. Science 1982;217:998–1003.
[73] Heppner GH. Tumor heterogeneity. Cancer Res 1984;44:2259–65.
[74] Nicolson GL. Generation of phenotypic diversity and progression in metastatic
tumor cells. Cancer Metastasis Rev 1984;3:25–42.
[75] Merlo LM,  Pepper JW,  Reid BJ, Maley CC. Cancer as an evolutionary and eco-
logical process. Nat Rev Cancer 2006;6:924–35.
[76] Ardiani A, Gameiro SR, Palena C, Hamilton DH, Kwilas A, King TH, et al.
Vaccine-mediated immunotherapy directed against a transcription factor
driving the metastatic process. Cancer Res 2014;74:1945–57.
[77] Butler TP, Gullino PM.  Quantitation of cell shedding into efferent blood of
mammary adenocarcinoma. Cancer Res 1975;35:512–6.
[78] Tarin D, Price JE, Kettlewell MG,  Souter RG, Vass AC, Crossley B, et al. Mecha-
nisms of human tumor metastasis studied in patients with peritoneovenous
shunts. Cancer Res 1984;44:3584–92.
[79] Chambers AF, Naumov GN, Varghese HJ, Nadkarni KV, MacDonald IC, Groom
AC. Critical steps in hematogenous metastasis: an overview. Surg Oncol Clin
N  Am 2001;10:243–55.
[80] Fiddler IJ. Critical determinants of cancer metastasis: rationale for therapy.
Cancer Chemother Pharmacol 1999;43:S3–10.
[81] Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol
1992;3:65–71.
[82] Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis.
Cancer 1997;80:1529–37.
[83] Hunter KW,  Crawford NPS, Alsarraj J. Mechanisms of metastasis. Breast Cancer
Res 2008;10, http://dx.doi.org/10.1186/bcr1988.
[84] Nowell PC. The clonal evolution of tumor cell populations. Science
1976;194:23–8.
[85] Fidler IJ, Kripke ML.  Metastasis results from preexisting variant cells within a
malignant tumor. Science 1977;197:893–5.
[86] Kang Y, Siegel PM,  Shu W,  Drobnjak M,  Kakonen SM,  Cordón-Cardo C, et al. A
multigenic program mediating breast cancer metastasis to bone. Cancer Cell
2003;3:537–49. Biology 35 (2015) S185–S198
[87] Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W,  Giri DD, et al. Genes that mediate
breast cancer metastasis to lung. Nature 2005;436:518–24.
[88] Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, et al. Dis-
tinct organ-speciﬁc metastatic potential of individual breast cancer cells and
primary tumors. J Clin Investig 2005;115:44–55.
[89] Mundy GR. Mechanisms of bone metastasis. Cancer 1997;80:1546–56.
[90] Cooke VG, LeBleu VS, Keskin D, Khan Z, O’Connell JT, Teng Y, et al. Pericyte
depletion results in hypoxia-associated epithelial-to-mesenchymal tran-
sition and metastasis mediated by met  signaling pathway. Cancer Cell
2012;21:66–81.
[91] Branco-Price C, Zhang N, Schnelle M,  Evans C, Katschinski DM,  Liao D, et al.
Endothelial cell HIF-1 and HIF-2 differentially regulate metastatic success.
Cancer Cell 2012;21:52–65.
[92] Kashiwagi S, Izumi Y, Gohongi T, Demou ZN, Xu L, Huang PL, et al. NO mediates
mural cell recruitment and vessel morphogenesis in murine melanomas and
tissue-engineered blood vessels. J Clin Investig 2005;115:1816–27.
[93] Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, et al. Hypoxia-induced
lysyl oxidase is a critical mediator of bone marrow cell recruitment to form
the premetastatic niche. Cancer Cell 2009;15:35–44.
[94] Sceneay J, Chow MT, Chen A, Halse HM,  Wong CS, Andrews DM,  et al. Primary
tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells
and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res
2012;72:3906–11.
[95] Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, et al. Silencing of Irf7
pathways in breast cancer cells promotes bone metastasis through immune
escape. Nat Med  2012;18(August (8)).
[96] Mackall CL. T-cell immunodeﬁciency following cytotoxic antineoplastic ther-
apy: a review. Stem Cells 2000;18:10–8.
[97] Noonan FP, Halliday FJ, Wall DR, Clunie GJA. Cell-mediated immunity
and serum blocking factors in cancer patients during chemotherapy and
immunotherapy. Cancer Res 1977;37:2473–80.
[98] Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimu-
lation by anticancer drugs. Nat Rev Drug Discov 2012;11:215–33.
[99] Loi S, Pommey S, Haibe-Kains B, Beavis PA, Darcy PK, Smyth MJ,  et al. CD73 pro-
motes anthracycline resistance and poor prognosis in triple negative breast
cancer. Proc Natl Acad Sci USA 2013;110:11091–6.
[100] Garnett CT, Scholm J, Hodge JW.  Combination of docetaxel and recombi-
nant vaccine enhances T-cell responses and anti-tumor activity; effects of
docetaxel on immune enhancement. Clin Cancer Rev 2008;14:3536–44.
[101] Hodge JW,  Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, et al.
Chemotherapy-induced immunogenic modulation of tumor cells enhances
killing by cytotoxic T lymphocytes and is distinct from immunogenic cell
death. Int J Cancer 2013;133:624–36.
[102] Uzawa A, Suzuki G, Kakata Y, Akashi M,  Ohyama Hakanuma A. Radiosensiti-
vity of CD45RO+ memory and CD45RO+ naïve T cells in culture. Radiat Res
1994;137:25–33.
[103] Ferguson RM,  Sutherland DE, Kim T, Simmons RL, Najarian JS. The in vitro
assessment of the immunesuppressive effect of fractionated total lymphoid
irradiation in renal allotransplantation. Transplant Proc 1981;13:1673–5.
[104] Lander HM,  Tauras JM,  Ogiste JS, Hori O, Moss RA, Schmidt AM.  Activation
of  the receptor for advanced glycation end products triggers a p21(ras)-
dependent mitogen-activated protein kinase pathway regulated by oxidant
stress. J Biol Chem 1997;272:17810–4.
[105] Kasid U, Suy S, Dent P, Whiteside TL, Sturgill TW.  Activation of Raf by ionizing
radiation. Nature 1996;382:813–6.
[106] Ifeadi V, Garnett-Benson C. Sub-lethal irradiation of colorectal tumor cells
imparts enhanced and sustained susceptibility to multiple death receptor
signialing pathways. PLoS ONE 2012;7:e31762.
[107] Matsumura S, Demaria S. Up-regulation of the proinﬂammatory chemokine
CXCL16 is a common response of tumors cells to ionization radiation. Radiat
Res 2010;173:418–25.
[108] Garnett CT, Palena C, Chakraborty M,  Tsang K, Scholm J, Hodge JW.  Sub-lethal
irradiation of human tumor cells modulates phenotype resulting in enhanced
killing by cytotoxic T lymphocytes. Cancer Res 2004;64:7985–94.
[109] Kumari A, Cacan E, Greer SF, Garnett-Benson C. Turning T cells on: epige-
netically enhanced effector T-cell activity following tumor cells irradiation. J
Immunother Cancer 2013;1:17, http://dx.doi.org/10.1186/2052-1426-1-17.
[110] Bernstein M,  Garnett CT, Zhang H, Velcich A, Wattenberg M,  Gameiro
S,  et al. radiation-induced modulation of costimulatory and coinhibitory
T-cell signaling molecules on human prostate carcinoma cells promotes
productive anti-tumor immune interactions. Cancer Biother Radiopharm
2014;29:153–61.
[111] Chakraborty M,  Abrams SI, Coleman CN, Camphausen K, Scholm J, Hodge
JW.  External beam radiation of tumors alters phenotype of tumor cells
to  render them susceptible to vaccine-mediated T-cell killing. Cancer Res
2004;64:4328–37.
[112] McBride WH,  Chiang CS, Olson JL, Wang CC, Hong JH, Pajonik F, et al. A sense
of danger from radiation. Radiat Res 2004;162:1–19.
[113] Ishihara H, Tanaka I, Nemoto K, Tsuneoka K, Cheeramakara C, Yoshida K.
Immediate-early, transient induction of the interleukin-1 beta gene in mouse
spleen macrophages by ionizing radiation. J Radiat Res 1995;36:112–24.
[114] Ehlers G, Fridman M. Abscopal effect of radiation in papillary adenocarcinoma.
Br  J Radiol 1973;46:220–2.
[115] Demaria S, Ng B, Devitt ML,  Babb JS, Kawashima L, Liebes L, et al. Inozation
radiation of distinct unrelated tumors (abscopal effect) is immune mediated.
Int J Radiat Oncol Biol Phys 2004;58:862–70.
ancer
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
adenosine receptor protects tumors from anti-tumor T cells. Proc Natl AcadD.S. Vinay et al. / Seminars in C
116] Durante M,  Reppingen N, Held KD. Immunologically augmented cancer treat-
ment using modern radiotherapy. Trends Mol  Med  2013;(13):00096–8, pii:
S1471-4914.
117] Sylla P, Kirman I, Whelan RL. Immunological advantages of advanced
laparoscopy. Surg Clin N Am 2005;85:1–18.
118] Gabay C, Kushner I. Acute-phase proteins and other systemic responses to
inﬂammation. N Engl J Med  1999;340:448–54.
119] Lennard TW,  Shenton BK, Borzotta A, Donnelly PK, White M, Gerrie LM, et al.
The inﬂuence of surgical operations on components of the human immune
system. Br J Surg 1985;72:771–6.
120] Whelan RL, Franklin M,  Holubar SD, Donahue J, Fowler R, Munger C. Postop-
erative cell mediated immune response is better preserved after laparoscopic
vs  open colorectal resection in humans. Surg Endosc 2003;17:972–8.
121] Zhang P, Cote AL, de vriess VC, Usherwood EJ, Turk MJ. Induction of post-
surgical immunity and T-cell memory by a poorly immunogenic tumor.
Cancer Res 2007;67:6468–76.
122] Belanich M,  Randall T, Pastor MA,  Kibitel JT, Alas LG, Dolan ME,  et al. Intracel-
lular  localization and intercellular heterogeneity of the human DNA repair
protein O(6)-methylguanine-DNA methyltransferase. Cancer Chemother
Pharmacol 1996;37:547–55.
123] Hotta T, Saito Y, Fujita H, Mikami T, Kurisu K, Kiya K, et al. O6-alkylguanine-
DNA alkyltransferase activity of human malignant glioma and its clinical
implications. J Neurooncol 1994;21:135–40.
124] Sleeman J, Steeg PS. Cancer metastasis as a therapeutic target. Eur J Cancer
2010;46:1177–80.
125] Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R.
Strategies for immunotherapy of cancer. Adv Immunol 2002;75:235–82.
126] Itok K, Yamada A. Personalized peptide vaccines: a new therapeutic modality
for cancer. Cancer Sci 2006;97:970–6.
127] Gilboa E. DC-based cancer vaccines. J Clin Investig 2007;117:1195–203.
128] Hodge JW,  Higgins J, Schlom J. Harnessing the unique local immunostimula-
tory properties of modiﬁed vaccinia Ankara (MVA) virus to generate superior
tumor-speciﬁc immune responses and anti-tumor activity in a diversiﬁed
prime and boost vaccine regimen. Vaccine 2009;27:4475–82.
129] Scholm J, Hodge JW,  Palena C, Tsang KY, Jochems C, greiner JW.  Therapeutic
cancer vaccines. Adv Cancer Res 2014;121:67–124.
130] June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Investig
2007;117:1466–76.
131] Patyar S, Joshi R, Byrav DS, Prakash A, Medhi B, Das BK. Bacteria in cancer
therapy: a novel experimental strategy. J Biomed Sci 2010;17, doi:1186/1423-
0127-17-21.
132] Xu J, Liu XS, Zhou SF, Wei  MQ.  Combination of immunotherapy with aner-
obic bacteria for immunogene therapy of solid tumors. Gene Ther Mol  Biol
2009;13:36–52.
133] Andersen MH.  The speciﬁc targeting of immune regulation: T-cell responses
against indoleamine 2,3-dioxygenase. Cancer Immunol Immunother
2012;61:1289–97.
134] Byrne WL,  Mills KH, Lederer JA, O’Sullivan GC. Targeting regulatory T cells in
cancer. Cancer Res 2011;71:6915–20.
135] Rasku MA,  Clem AL, Telang S, Taft B, Gettings K, Gragg H, et al. Transient T cell
depletion causes regression of melanoma metastases. J Transl Med  2008;6:12,
http://dx.doi.org/10.1186/1479-5876-6-12.
136] Marigo I, Dolcetti L, Seraﬁni P, Zanovello P, Bronte V. Tumor-induced tolerance
and immune suppression by myeloid derived suppressor cells. Immunol Rev
2008;222:162–79.
137] Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mecha-
nisms for inhibiting antitumor immunity. Cancer Immunol Immunother
2010;59:1593–600.
138] Kim YS, Kim YJ, Lee JM,  Kim EK, Park YJ, Choe SK, et al. Functional changes
in  myeloid-derived suppressor cells (MDSCs) during tumor growth: FKBP51
contributes to the regulation of the immunosuppressive function of MDSCs.
J  Immunol 2012;188:4226–34.
139] Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of
the  immune system. Nat Rev Immunol 2009;9:162–74.
140] Melancon MP,  Lu W,  Huang Q, Thapa P, Zhou D, Ng C, et al. Targeted imaging
of  tumor-associated M2  macrophages using a macromolecular contrast agent
PG-Gd-NIR813. Biomaterials 2010;31:6567–73.
141] Barten R, Torkar M,  Haude A, Trowsdale J, Wilson MJ. Divergent and conver-
gent evolution of NK-cell receptors. Trends Immunol 2001;22:52–7.
142] George TC, Ortaldo JR, Lemieux S, Kumar V, Bennett M.  Tolerance and
alloreactivity of the Ly49D subset of murine NK cells. J Immunol 1999;163:
1859–67.
143] Schmidt SV, Nino-Castro AC, Schultze JL. Regulatory dendritic cells:
there is more than just immune activation. Front Immunol 2012;3:274,
http://dx.doi.org/10.3389/ﬁmmu.2012.00274.
144] Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev
Cancer 2012;12:265–77.
145] Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clin-
ical response and immune-related adverse events. Oncologist 2007;12:
864–72.
146] Vinay DS, Kwon BS. Immunotherapy of cancer with 4-1BB. Mol  Cancer Ther
2012;11:1062–70.147] Topalian SL, Drake CG, Pardoll DM.  Targeting the PD-1/B7-H1(PD-L1) pathway
to  activate antitumor immunity. Curr Opin Immunol 2012;24:207–12.
148] Kim YS, Jung HW,  Choi J, Kwon BS, Ham SY, Jung AK, et al. Expression of AITR
and  AITR ligand in breast cancer patients. Oncol Rep 2007;18:1189–94. Biology 35 (2015) S185–S198 S195
[149] Shashidharamurthy R, Bozeman EN, Patel J, Kaur R, Meganathan J, Selvaraj P.
Immunotherapeutic strategies for cancer treatment: a novel protein transfer
approach for cancer vaccine development. Med  Res Rev 2012;32:1197–219.
[150] Rosenberg SA. A new era for cancer immunotherapy based on the genes that
encode cancer antigens. Immunity 1999;10:281–7.
[151] Van den Eynde BJ, van der Bruggen P. T cell deﬁned tumor antigens. Curr Opin
Immunol 1997;9:684–93.
[152] Chen YT, Scanlan MJ,  Sahin U, Türeci O, Gure AO, Tsang S, et al. A testicular anti-
gen aberrantly expressed in human cancers detected by autologous antibody
screening. Proc Nat Acad Sci USA 1997;94:1914–8.
[153] Ikeda H, Lethé B, Lehmann F, van Baren N, Baurain JF, de Smet C, et al. Charac-
terization of an antigen that is recognized on a melanoma showing partial HLA
loss by CTL expressing an NK inhibitory receptor. Immunity 1997;6:199–208.
[154] Liu L, Lai S, Andrews LG, Tollefsbol TO. Genetic and epigenetic modulation of
telomerase activity in development and disease. Gene 2004;340:1–10.
[155] Gu J, Kagawa S, Takakura M,  Kyo S, Inoue M,  Roth JA, et al. Tumor-speciﬁc
transgene expression from the human telomerase reverse transcriptase pro-
moter enables targeting of the therapeutic effects of the Bax gene to cancers.
Cancer Res 2000;60:5359–64.
[156] Koga S, Hirohata S, Kondo Y, Komata T, Takakura M,  Inoue M,  et al. A
novel telomerase-speciﬁc gene therapy: gene transfer of caspase-8 utiliz-
ing the human telomerase catalytic subunit gene promoter. Hum Gene Ther
2000;11:1397–406.
[157] Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, et al. Expression of the
Wilms’ tumor gene WT1  in solid tumors and its involvement in tumor cell
growth. Jpn J Cancer Res 1999;90:194–204.
[158] Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H, et al. Human cytotoxic
T-lymphocyte responses speciﬁc for peptides of the wild-type Wilms’ tumor
gene (WT1) product. Immunogenetics 2000;51:99–107.
[159] Oka Y, Tsuboi A, Kawakami M,  Elisseeva OA, Nakajima H, Udaka K, et al. Devel-
opment of WT1  peptide cancer vaccine against hematopoietic malignancies
and solid cancers. Curr Med Chem 2006;13:2345–52.
[160] Wolchok J. How recent advances in immune therapy are changing the
standard care for patients with metastatic melanoma. Ann Oncol 2012;23,
viii5-viii21.
[161] Hodi FS, O’Day SJ, McDermott DF, Weber RW,  Sosman JA, Haanen JB, et al.
Improved survival with ipilimumab in patients with metastatic melanoma. N
Engl J Med 2010;363(8):711–23.
[162] Drake CG, Antonarakis ES. Current status of immunological approaches for
the treatment of prostate cancer. Curr Opin Urol 2012;22:197–202.
[163] Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al.
Ipilimumab in combination with Paciltaxel and Carboplatin as ﬁrst-line treat-
ment in stage IIIB/IV non-small-cell lung cancer: results from a randomized,
double-blinded, multicenter phase II study. J Clin Oncol 2012;30:2046–54.
[164] Yang JC, Hughes M,  Kammula U. Ipilimumab (anti-CTLA-4 antibody) causes
regression of metastatic renal cells cancer as dissociated with enteritis and
hypophysitis. J Immunother 2007;30:825–30.
[165] Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF,
et  al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
N  Engl J Med  2012;366:2443–54.
[166] Melero I, Grimaldi AM,  Perez-Gracia JL, Ascierto PA. Clinical development of
immunostimulatory monoclonal antibodies and opportunities for combina-
tion. Clin Cancer Res 2013;19:997–1008.
[167] Jing W,  Yan X, Hallett WH,  Gershan JA, Johnson BD. Depletion of CD25+ T cells
from hematopoietic stem cell grafts increases posttransplantation vaccine-
induced immunity to neuroblastoma. Blood 2011;117:6952–62.
[168] Nefedova Y, Huang M,  Kusmartsev S, Bhattacharya R, Cheng P, Salup R, et al.
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic
cells in cancer. J Immunol 2004;172:464–74.
[169] Wang X, Crowe PJ, Goldstein D, Yang JL. STAT3 inhibition, a novel approach
to  enhancing targeted therapy in human cancers. Int J Oncol 2012;41:
1181–91.
[170] Stagg J, Smyth MJ. Extracellular adenosine triphosphatase and adenosine in
cancer. Oncogene 2010;29:5346–58.
[171] Beavis PA, Divisekera U, Paget C, Chow MT,  John LB, Devaud C, et al. Blockade
of  A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc
Natl Acad Sci USA 2013;110:14711–6.
[172] Allard B, Pommey S, Smyth MJ,  Stagg J. Targeting CD73 enhances the
anti-tumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Can Res
2013;19(20):5626–35.
[173] Beavis PA, Stagg J, Darcy PK, Smyth MJ.  CD73: a potent suppressor of antitumor
immune responses. Trends Immunol 2012;33:231–7.
[174] Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, et al.
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.
Proc Natl Acad Sci USA 2010;107:1547–52.
[175] Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW,  Darcy PK, et al.
CD73-deﬁcient mice have increased antitumor immunity and are resistant
to experimental metastasis. Cancer Res 2011;71:2892–900.
[176] Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW,  Darcy PK, et al. CD73-
deﬁcient mice are resistant to carcinogenesis. Cancer Res 2011;71:2892–900.
[177] Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MKK, et al. A2ASci  USA 2006;103:13132–7.
[178] Gulley JL, Madan RA, Tsang KY, Jochems C, Marte JL, Farsaci B, et al.
Immune impact induced by PROSTVAC (PSA-TRICOM) a therapeutic vaccine
for  prostate cancer. Cancer Immunol Res 2013;2:133–41.
S ancer196 D.S. Vinay et al. / Seminars in C
[179] Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM,
et al. Cancer immunotherapy with peptide-based vaccines: what have we
achieved? Where are we going? J Natl Can Inst 2002;94:805–18.
[180] Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, et al.
Induction of tumor-reactive CTL from peripheral blood and tumor-inﬁltrating
lymphocytes of melanoma patients by in vitro stimulation with an immu-
nodominant peptide of the human melanoma antigen MART-1. J Immunol
1995;154:2257–65.
[181] Cormier JN, Salgaller ML,  Prevette T, Barracchini KC, Rivoltini L, Restifo NP,
et al. Enhancement of cellular immunity in melanoma patients immunized
with a peptide from MART-1/Melan A. Cancer J Sci Am 1997;3:37–44.
[182] Salgaller ML,  Afshar A, Marincola FM,  Rivoltini L, Kawakami Y, Rosenberg SA.
Recognition of multiple epitopes in the human melanoma antigen gp100 by
peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
Cancer Res 1995;55:4972–9.
[183] Marchand M,  van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH,  et al.
Tumor regressions observed in patients with metastatic melanoma treated
with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.
Int J Cancer 1999;80:219–30.
[184] Weber JS, Hua FL, Spears L, Marty V, Kuniyoshi C, Celis E. A phase I trial
of  an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Fre-
und’s adjuvant in patients with resected high-risk melanoma. J Immunother
1999;22:431–40.
[185] Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for acti-
vating effective immunity against cancer. Nat Rev Cancer 2008;8:108–20.
[186] Lin MA.  DNA vaccines: an historical perspective and view to the future.
Immunol Rev 2011;239:62–84.
[187] Chiarella P, Fazio VM,  Signori E. Electroporation in DNA vaccination protocols
against cancer. Curr Drug Metab 2013;14(3):291–9.
[188] Mir  LM,  Bureau MF,  Gehl J, Rangara R, Rouy D, Caillaud JM, et al. High-
efﬁciency gene transfer into skeletal muscle mediated by electric pulses. Proc
Natl Acad Sci USA 1999;96:4262–7.
[189] Chiarella P, Massi E, De Robertis M, Sibilio A, Parrella P, Fazio VM,  et al.
Electroporation of skeletal muscle induces danger signal release and antigen-
presenting cell recruitment independently of DNA vaccine administration.
Expert Opin Biol Ther 2008;8:1645–57.
[190] Lichtor T, Glick RP, Lin H, O-Sullivan I, Cohen EP. Intratumoral injection of IL-
secreting syngeneic/allogeneic ﬁbroblasts transfected with DNA from breast
cancer cells prolongs the survival of mice with intracerebral breast cancer.
Cancer Gene Ther 2005;12:708–14.
[191] Lichtor T, Glick RP, Feldman LA, Osawa G, Hardman J, O-Sullivan I, et al.
Enhanced immunity to intracerebral breast cancer in mice immunized with
a  cDNA-based vaccine enriched for immunotherapeutic cells. J Immunother
2008;31:18–27.
[192] Nestle FO. Dendritic cell vaccination for cancer therapy. Oncogene
2000;19:6673–9.
[193] Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C,
et  al. Multipeptide immune response to cancer vaccine IMA901 after single-
dose cyclophosphamide associates with longer patient survival. Nat Med
2012:1254–61.
[194] Lutsiak ME,  Semnani RT, De Pascalis R, Kashmiri SV, Scholm J, Sabzevari H.
Inhibition of CD(+)CD25+ T regulatory cell function implicated in enhanced
immune response by low-dose cycloohosphamide. Blood 2005;105:2862–8.
[195] Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines.
Immunity 2013;39:38–48.
[196] Kantoff PW,  Higano CS, Shore ND, Berger ED, Small EJ, penson DF, et al.
Sipuleuciel-T immunotherapy for castration-resistant prostate cancer. N Engl
J  Med  2010;363:411–22.
[197] Russo M,  Spagnuolo C, Tedesco I, Russo GL. Phytochemicals in cancer preven-
tion  and therapy: truth or dare? Toxins 2010;2:517–51.
[198] Middleton Jr E, Kandaswami C. Effects of ﬂavonoids on immune and inﬂam-
matory cell functions. Biochem Pharmacol 1992;43:1167–79.
[199] Calder PC. Immunomodulation by omega-3 fatty acids. Prostaglandins Leukot
Essent Fatty Acids 2007;77:327–35.
[200] Dardenne M.  Zinc and immune function. Eur J Clin Nutr 2002;56:520–3.
[201] Calder PC, Kew S. The immune system: a target for functional foods? Br J Nutr
2002;88:S165–76.
[202] Hughes DA. Dietary carotenoids and human immune function. Nutrition
2001;10:823–7.
[203] Kodama N, Komuta K, Nanba H. Effect of Maitake (Grifola frondosa) D-fraction
on the activation of NK cells in cancer patients. J Med  Food 2003;6:371–7.
[204] Cole BF, Baron JA, Sandler RS, Haile RW,  Ahnen DJ, Bresalier RS, et al. Folic acid
for the prevention of colorectal adenomas: a randomized clinical trial. JAMA
2007;6:2351–9.
[205] Rock CL. Multivitamin-multimineral supplements: who  uses them? Am J Clin
Nutr 2007;85:2775–95.
[206] Kim J, Denu RA, Dollar BA, Escalante LE, Kuether JP, Callander NS, et al.
Macrophages and mesenchymal stromal cells support survival and prolif-
eration of multiple myeloma cells. Br J Haematol 2012;158:336–46.
[207] Singh AK, Gaur P, Das SN. Natural killer T cell anergy, co-stimulatory molecules
and immunotherapeutic interventions. Hum Immunol 2014;75:250–60.[208] Ito Y, Vela JL, Matsumura F, Hoshino H, Tyznik A, Lee H, et al. Helicobacter
pylori cholesteryl -glucosides contribute to its pathogenicity and immune
response by natural killer T cells. PLOS ONE 2013;8(12):e78191.
[209] Jameson J, Witherden D, Havran WL.  T-cell effector mechanisms: gammadelta
and  CD1d-restricted subsets. Curr Opin Immunol 2003;15:349–53. Biology 35 (2015) S185–S198
[210] Cheng C, Huang C, Ma  TT, Bian EB, He Y, Zhang L, et al. SOCS1 hypermeth-
ylation mediated by DNMT1 is associated with lipopolysaccharide-induced
inﬂammatory cytokines in macrophages. Toxicol Lett 2014;225:488–97.
[211] Strauss L, Bergmann C, Gooding W,  Johnson JT, Whiteside TL. The frequency
and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of
patients with squamous cell carcinoma of the head and neck. Clin Cancer Res
2007;13:6301–11.
[212] Stewart CA, Metheny H, Iida N, Smith L, Hanson M,  Steinhagen F, et al.
Interferon-dependent IL-10 production by Tregs limits tumor Th17 inﬂam-
mation. J Clin Investig 2013;123:4859–74.
[213] Whiteside TL, Schuler P, Schilling B. Induced and natural regulatory T cells in
human cancer. Expert Opin Biol Ther 2012;12:1383–97.
[214] Jia Y, Guan Q, Guo Y, Du C. Reduction of inﬂammatory hyperplasia in the intes-
tine in colon cancer-prone mice by water-extract of Cistanche deserticola.
Phytother Res 2012;26:812–9.
[215] Elkabets M,  Ribeiro VS, Dinarello CA, Ostrand-Rosenberg S, Di Santo JP, Apte
RN, et al. IL-1 regulates a novel myeloid-derived suppressor cell subset that
impairs NK cell development and function. Eur J Immunol 2010;40:3347–57.
[216] Albulescu R, Codrici E, Popescu ID, Mihai S, Necula LG, Petrescu D,
et  al. Cytokine patterns in brain tumour progression. Mediat Inﬂamm
2013;2013:979748.
[217] Day SD, Enos RT, McClellan JL, Steiner JL, Velázquez KT, Murphy EA. Linking
inﬂammation to tumorigenesis in a mouse model of high-fat-diet-enhanced
colon cancer. Cytokine 2013;64:454–62.
[218] Fowler DW,  Copier J, Wilson N, Dalgleish AG, Bodman-Smith MD. Mycobacte-
ria  activate  T-cell anti-tumour responses via cytokines from type 1 myeloid
dendritic cells: a mechanism of action for cancer immunotherapy. Cancer
Immunol Immunother 2012;61:535–47.
[219] Fu Z, Zuo Y, Li D, Xu W,  Li D, Chen H, et al. The crosstalk: tumor-inﬁltrating lym-
phocytes rich in regulatory T cells suppressed cancer-associated ﬁbroblasts.
Acta Oncol 2013;52:1760–70.
[220] Pahl JH, Ruslan SE, Buddingh EP, Santos SJ, Szuhai K, Serra M, et al. Anti-
EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells
toward osteosarcoma. Clin Cancer Res 2012;18:432–41.
[221] Martinet W,  De Meyer I, Verheye S, Schrijvers DM,  Timmermans JP, De Meyer
GR.  Drug-induced macrophage autophagy in atherosclerosis: for better or
worse? Basic Res Cardiol 2013;108:321.
[222] Li N, Ma T, Han J, Zhou J, Wang J, Zhang J, et al. Increased apoptosis induc-
tion in CD4+CD25+ Foxp3+ T cells contributes to enhanced disease activity
in patients with rheumatoid arthritis through Il-10 regulation. Eur Rev Med
Pharmacol Sci 2014;18:78–85.
[223] Kawabe K, Lindsay D, Braitch M,  Fahey AJ, Showe L, Constantinescu CS. IL-
12  inhibits glucocorticoid-induced T cell apoptosis by inducing GMEB1 and
activating PI3K/Akt pathway. Immunobiology 2012;217:118–23.
[224] Iannello A, Thompson TW,  Ardolino M, Lowe SW,  Raulet DH. p53-dependent
chemokine production by senescent tumor cells supports NKG2D-dependent
tumor elimination by natural killer cells. J Exp Med  2013;210:2057–69.
[225] Yao L, Sgadari C, Furuke K, Bloom ET, Teruya-Feldstein J, Tosato G. Contri-
bution of natural killer cells to inhibition of angiogenesis by interleukin-12.
Blood 1999;93:1612–21.
[226] Naldini A, Pucci A, Bernini C, Carraro F. Regulation of angiogenesis by Th1-
and Th2-type cytokines. Curr Pharm Des 2003;9:511–9.
[227] Larsen H, Muz  B, Khong TL, Feldmann M,  Paleolog EM.  Differential effects of
Th1  versus Th2 cytokines in combination with hypoxia on HIFs and angio-
genesis in RA. Arthritis Res Ther 2012;14:R180 [Epub ahead of print].
[228] Rankin EB, Yu D, Jiang J, Shen H, Pearce EJ, Goldschmidt MH,  et al. An essential
role of Th1 responses and interferon gamma in infection-mediated suppres-
sion of neoplastic growth. Cancer Biol Ther 2003;2:687–93.
[229] Caccamo N, Dieli F, Meraviglia S, Guggino G, Salerno A. Gammadelta
T  cell modulation in anticancer treatment. Curr Cancer Drug Targets
2010;10:27–36.
[230] Meraviglia S, Eberl M,  Vermijlen D, Todaro M,  Buccheri S, Cicero G, et al.
In  vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-
dose interleukin-2 for immunotherapy of advanced breast cancer patients.
Clin Exp Immunol 2010;161:290–7.
[231] Gomes AQ, Martins DS, Silva-Santos B. Targeting  T lymphocytes for can-
cer immunotherapy: from novel mechanistic insight to clinical application.
Cancer Res 2010;70:10024–7.
[232] Wakita D, Sumida K, Iwakura Y, Nishikawa H, Ohkuri T, Chamoto K, et al.
Tumor-inﬁltrating IL-17-producing gammadelta T cells support the progres-
sion of tumor by promoting angiogenesis. Eur J Immunol 2010;40:1927–37.
[233] Pakala R, Watanabe T, Benedict CR. Induction of endothelial cell prolifera-
tion by angiogenic factors released by activated monocytes. Cardiovasc Radiat
Med  2002;3:95–101.
[234] Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, et al.
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg)
cells. Nature 2011;475:226–30.
[235] Voest EE, Kenyon BM,  O’Reilly MS,  Truitt G, D’Amato RJ, Folkman J. Inhibition
of  angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995;87:581–6.
[236] Budhu A, Forgues M,  Ye QH, Jia HL, He P, Zanetti KA, et al. Prediction of venous
metastases, recurrence, and prognosis in hepatocellular carcinoma based on
a  unique immune response signature of the liver microenvironment. Cancer
Cell  2006;10:99–111.
[237] Ferrarini M, Ferrero E, Dagna L, Poggi A, Zocchi MR. Human gammadelta T
cells: a nonredundant system in the immune-surveillance against cancer.
Trends Immunol 2002;23:14–8.
ancer
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[D.S. Vinay et al. / Seminars in C
238] Pollard JW.  Tumour-educated macrophages promote tumour progression and
metastasis. Nat Rev Cancer 2004;4:71–8.
239] DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawﬁk D, Kolhatkar N,
et  al. CD4(+) T cells regulate pulmonary metastasis of mammary carci-
nomas by enhancing protumor properties of macrophages. Cancer Cell
2009;16:91–102.
240] Smyth MJ,  Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, et al.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes
to interferon gamma-dependent natural killer cell protection from tumor
metastasis. J Exp Med  2001;193:661–70.
241] Shen F, Li JL, Cai WS,  Zhu GH, Gu WL,  Jia L, et al. Interleukin-12 pre-
vents colorectal cancer liver metastases in mice. OncoTargets Ther 2013;6:
523–6.
242] Thakur A, Schalk D, Sarkar SH, Al-Khadimi Z, Sarkar FH, Lum LG.
A  Th1 cytokine-enriched microenvironment enhances tumor killing by
activated T cells armed with bispeciﬁc antibodies and inhibits the devel-
opment of myeloid-derived suppressor cells. Cancer Immunol Immunother
2012;61:497–509.
243] Ye J, Ma C, Wang F, Hsueh EC, Toth K, Huang Y, et al. Speciﬁc recruitment of
  regulatory T cells in human breast cancer. Cancer Res 2013;73:6137–48.
244] Lamagna C, Aurrand-Lions M,  Imhof BA. Dual role of macrophages in tumor
growth and angiogenesis. J Leukoc Biol 2006;80:705–13.
245] Schoppmann SF, Birner P, Stöckl J, Kalt R, Ullrich R, Caucig C, et al. Tumor-
associated macrophages express lymphatic endothelial growth factors and
are related to peritumoral lymphangiogenesis. Am J Pathol 2002;161:947–56.
246] Tsung K, Dolan JP, Tsung YL, Norton JA. Macrophages as effector cells
in  interleukin 12-induced T cell-dependent tumor rejection. Cancer Res
2002;62:5069–75.
247] Wu X, Peng M,  Huang B, Zhang H, Wang H, Huang B, et al. Immune microen-
vironment proﬁles of tumor immune equilibrium and immune escape states
of mouse sarcoma. Cancer Lett 2013;340:124–33.
248] Hayakawa Y, Sato-Matsushita M, Takeda K, Iwakura Y, Tahara H, Irimura
T.  Early activation and interferon- production of tumor-inﬁltrating mature
CD27 high natural killer cells. Cancer Sci 2011;102:1967–71.
249] Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, et al.
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells
within mouse tumors. J Clin Investig 2011;121:4746–57.
250] Schepetkin IA, Quinn MT.  Botanical polysaccharides: macrophage
immunomodulation and therapeutic potential. Int Immunopharmacol
2006;6:317–33.
251] Jeff IB, Yuan X, Sun L, Kassim RM,  Foday AD, Zhou Y. Puriﬁcation and in vitro
anti-proliferative effect of novel neutral polysaccharides from Lentinus edo-
des. Int J Biol Macromol 2013;52:99–106.
252] Zhao L, Xiao Y, Xiao N. Effect of lentinan combined with docetaxel and
cisplatin on the proliferation and apoptosis of BGC823 cells. Tumour Biol
2013;34:1531–6.
253] Wakshlag JJ, Balkman CA, Morgan SK, McEntee MC.  Evaluation of the protec-
tive effects of all-trans-astaxanthin on canine osteosarcoma cell lines. Am J
Vet  Res 2010;71:89–96.
254] Yasui Y, Hosokawa M,  Mikami N, Miyashita K, Tanaka T. Dietary astaxan-
thin inhibits colitis and colitis-associated colon carcinogenesis in mice via
modulation of the inﬂammatory cytokines. Chem Biol Interact 2011;193:
79–87.
255] Tanaka T, Kawamori T, Ohnishi M,  Makita H, Mori H, Satoh K, et al. Suppression
of  azoxymethane-induced rat colon carcinogenesis by dietary administration
of naturally occurring xanthophylls astaxanthin and canthaxanthin during
the postinitiation phase. Carcinogenesis 1995;16:2957–63.
256] Sliva D, Loganathan J, Jiang J, Jedinak A, Lamb JG, Terry C, et al. Mushroom
Ganoderma lucidum prevents colitis-associated carcinogenesis in mice. PLoS
ONE 2012;7:e47873.
257] Joseph S, Sabulal B, George V, Antony KR, Janardhanan KK. Antitumor and anti-
inﬂammatory activities of polysaccharides isolated from Ganoderma lucidum.
Acta Pharm 2011;61:335–42.
258] Yang B, Xiao B, Sun T. Antitumor and immunomodulatory activity of Astra-
galus membranaceus polysaccharides in H22 tumor-bearing mice. Int J Biol
Macromol 2013;62:287–90.
259] Nishitani Y, Zhang L, Yoshida M,  Azuma T, Kanazawa K, Hashimoto T, et al.
Intestinal anti-inﬂammatory activity of lentinan: inﬂuence on IL-8 and TNFR1
expression in intestinal epithelial cells. PLOS ONE 2013;8:e62441.
260] Bisen PS, Baghel RK, Sanodiya BS, Thakur GS, Prasad GB. Lentinus edo-
des: a macrofungus with pharmacological activities. Curr Med  Chem
2010;17:2419–30.
261] Speranza L, Pesce M,  Patruno A, Franceschelli S, de Lutiis MA,  Grilli A,
et  al. Astaxanthin treatment reduced oxidative induced pro-inﬂammatory
cytokines secretion in U937: SHP-1 as a novel biological target. Mar  Drugs
2012;10:890–9.
262] Hsieh TC, Wu JM.  Suppression of proliferation and oxidative stress by extracts
of  Ganoderma lucidum in the ovarian cancer cell line OVCAR-3. Int J Mol  Med
2011;28:1065–9.
263] Jiang J, Slivova V, Harvey K, Valachovicova T, Sliva D. Ganoderma lucidum sup-
presses growth of breast cancer cells through the inhibition of Akt/NF-kappaB
signaling. Nutr Cancer 2004;49:209–16.
264] Hsieh TC, Wu P, Park S, Wu JM.  Induction of cell cycle changes and modulation
of  apoptogenic/anti-apoptotic and extracellular signaling regulatory protein
expression by water extracts of I’m-Yunity (PSP). BMC  Complement Altern
Med  2006;6:30. Biology 35 (2015) S185–S198 S197
[265] Auyeung KK, Law PC, Ko JK. Astragalus saponins induce apoptosis via an
ERK-independent NF-kappaB signaling pathway in the human hepatocellular
HepG2 cell line. Int J Mol  Med  2009;23:189–96.
[266] Fang N, Li Q, Yu S, Zhang J, He L, Ronis MJ,  et al. Inhibition of growth and
induction of apoptosis in human cancer cell lines by an ethyl acetate fraction
from shiitake mushrooms. J Altern Complement Med  2006;12:125–32.
[267] Palozza P, Torelli C, Boninsegna A, Simone R, Catalano A, Mele MC,  et al.
Growth-inhibitory effects of the astaxanthin-rich alga Haematococcus pluvi-
alis in human colon cancer cells. Cancer Lett 2009;283:108–17.
[268] Gao Y, Gao H, Chan E, Tang W,  Xu A, Yang H, et al. Antitumor activity and
underlying mechanisms of ganopoly, the reﬁned polysaccharides extracted
from Ganoderma lucidum, in mice. Immunol Investig 2005;34:171–98.
[269] Wang T, Xuan X, Li M, Gao P, Zheng Y, Zang W,  et al. Astragalus saponins affect
proliferation, invasion and apoptosis of gastric cancer BGC-823 cells. Diagn
Pathol 2013;8:179.
[270] Wang KP, Zhang QL, Liu Y, Wang J, Cheng Y, Zhang Y. Structure and inducing
tumor cell apoptosis activity of polysaccharides isolated from Lentinus edodes.
J  Agric Food Chem 2013;61:9849–58.
[271] Kavitha K, Kowshik J, Kishore TK, Baba AB, Nagini S. Astaxanthin inhibits
NF-B  and Wnt/-catenin signaling pathways via inactivation of Erk/MAPK
and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer.
Biochim Biophys Acta 2013;1830:4433–44.
[272] Wesolowska O, Wisniewski J, Bielawska-Pohl A, Paprocka M,  Duarte N, Fer-
reira MJ,  et al. Stilbenes as multidrug resistance modulators and apoptosis
inducers in human adenocarcinoma cells. Anticancer Res 2010;30:4587–93.
[273] Yuen JW,  Gohel MD,  Au DW.  Telomerase-associated apoptotic events by
mushroom ganoderma lucidum on premalignant human urothelial cells. Nutr
Cancer 2008;60:109–19.
[274] Gao Y, Tang W,  Gao H, Chan E, Lan J, Zhou S. Ganoderma lucidum polysaccharide
fractions accelerate healing of acetic acid-induced ulcers in rats. J Med Food
2004;7:417–21.
[275] Cao QZ, Lin ZB. Antitumor and anti-angiogenic activity of Ganoderma lucidum
polysaccharides peptide. Acta Pharmacol Sin 2004;25:833–8.
[276] Zhang L, Yang Y, Wang Y, Gao X. Astragalus membranaceus extract promotes
neovascularisation by VEGF pathway in rat model of ischemic injury. Phar-
mazie 2011;66:144–50.
[277] Sano B, Sugiyama Y, Kunieda K, Sano J, Saji S. Antitumor effects induced by
the combination of TNP-470 as an angiogenesis inhibitor and lentinan as a
biological response modiﬁer in a rabbit spontaneous liver metastasis model.
Surg Today 2002;32:503–9.
[278] Kim DH, Hossain MA, Kim MY,  Kim JA, Yoon JH, Suh HS, et al. A novel
resveratrol analogue, HS-1793, inhibits hypoxia-induced HIF-1 and VEGF
expression, and migration in human prostate cancer cells. Int J Oncol
2013;43:1915–24.
[279] Sliva D, Labarrere C, Slivova V, Sedlak M,  Lloyd Jr FP, Ho NW.  Ganoderma
lucidum suppresses motility of highly invasive breast and prostate cancer
cells. Biochem Biophys Res Commun 2002;298:603–12.
[280] Liu X, Yang Y, Zhang X, Xu S, He S, Huang W,  et al. Compound Astragalus
and  Salvia miltiorrhiza extract inhibits cell invasion by modulating trans-
forming growth factor-beta/Smad in HepG2 cell. J Gastroenterol Hepatol
2010;25:420–6.
[281] Ren L, Perera C, Hemar Y. Antitumor activity of mushroom polysaccharides:
a  review. Food Funct 2012;3:1118–30.
[282] Ogasawara M,  Matsunaga T, Suzuki H. Differential effects of antioxidants on
the in vitro invasion, growth and lung metastasis of murine colon cancer cells.
Biol Pharm Bull 2007;30:200–4.
[283] Polonini HC, Lima LL, Gonc¸ alves KM,  do Carmo AM,  da Silva AD, Raposo
NR.  Photoprotective activity of resveratrol analogues. Bioorg Med  Chem
2013;21:964–8.
[284] Mikstacka R, Ignatowicz E. Chemopreventive and chemotherapeutic effect
of  trans-resveratrol and its analogues in cancer. Pol Merkur Lekarski
2010;28:496–500.
[285] Lu J, Sun LX, Lin ZB, Duan XS, Ge ZH, Xing EH, et al. Antagonism by Ganoderma
lucidum polysaccharides against the suppression by culture supernatants of
B16F10 melanoma cells on macrophage. Phytother Res 2014;28:200–6.
[286] Ono Y, Hayashida T, Konagai A, Okazaki H, Miyao K, Kawachi S, et al.
Direct inhibition of the transforming growth factor- pathway by protein-
bound polysaccharide through inactivation of Smad2 signaling. Cancer Sci
2012;103:317–24.
[287] Li Q, Bao JM, Li XL, Zhang T, Shen XH. Inhibiting effect of Astragalus
polysaccharides on the functions of CD4+CD25 highTreg cells in the tumor
microenvironment of human hepatocellular carcinoma. Chin Med J (Engl)
2012;125:786–93.
[288] Zong A, Cao H, Wang F. Anticancer polysaccharides from natural resources: a
review of recent research. Carbohydr Polym 2012;904:1395–410.
[289] Nagendraprabhu P, Sudhandiran G. Astaxanthin inhibits tumor invasion by
decreasing extracellular matrix production and induces apoptosis in exper-
imental rat colon carcinogenesis by modulating the expressions of ERK-2,
NFkB and COX-2. Investig New Drugs 2011;29:207–24.
[290] Choi YJ, Yang KM,  Kim SD, Yoo YH, Lee SW,  Seo SY, et al. Resveratrol ana-
logue HS-1793 induces the modulation of tumor-derived T cells. Exp Ther
Med  2012;3:592–8.
[291] Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG.  Cellular and genetic
mechanisms of self tolerance and autoimmunity. Nature 2005;435:590–7.
[292] Rosenberg SA, Packard BS, Aebersold PM,  Solomon D, Topalian SL, Toy
ST,  et al. Use of tumor-inﬁltrating lymphocytes and interleukin-2 in the
S ancer198 D.S. Vinay et al. / Seminars in C
immunotherapy of patients with metastatic melanoma. A preliminary report.
N  Engl J Med  1988;319:1676–80.
[293] Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber
JS,  et al. Treatment of patients with metastatic melanoma with autolo-
gous tumor-inﬁltrating lymphocytes and interleukin 2. J Natl Cancer Inst
1994;86:1159–66.
[294] Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu  P, Schwartzentruber DJ,
et  al. Cancer regression and autoimmunity in patients after clonal repopula-
tion  with antitumor lymphocytes. Science 2002;298:850–4.
[295] Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME.  Adoptive cell
transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer
2008;8:299–308.
[296] Schietinger A, Delrow JJ, Basom RS, Blattman JN, Greenberg PD. Rescued toler-
ant CD8 T cells are preprogrammed to reestablish the tolerant state. Science
2012;335:723–7.
[297] King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T
cells during immune insufﬁciency generates autoimmunity. Cell 2004;117:
265–77. Biology 35 (2015) S185–S198
[298] Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, et al. Characteriza-
tion of circulating T cells speciﬁc for tumor-associated antigens in melanoma
patients. Nat Med 1999;5:677–85.
[299] Nagorsen D, Scheibenbogen C, Marincola FM,  Letsch A, Keilholz U. Natural T
cell  immunity against cancer. Clin Cancer Res 2003;9:4296–303.
[300] Rosenberg SA, Yang JC, Sherry RM,  Kammula US, Hughes MS,  Phan GQ,
et  al. Durable complete responses in heavily pretreated patients with
metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res
2011;17:4550–7.
[301] Rosenberg SA, Yang C, White DE. Recombinant fowlfox viruses encod-
ing the anchor-modiﬁed gp100 melanoma antigen can generate antitumor
immune response in patients with metastatic melanoma. Clin Cancer Res
2003;9:2973–80.[302] Choi BK, Lee SC, Lee MJ,  Kim YH, Kim YW,  Ryu KW,  et al. 4-1BB-based isolation
and expansion of CD8+ T cells speciﬁc for self and non-self tumor antigens
for adoptive T cell therapy. J Immunother 2014;37:225–36.
[303] Kalos M. Muscle CARs and TcRs: turbo-charged technologies for the (T cell)
masses. Cancer Immunol Immunother 2012;61:127–35.
